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EXECUTIVE SUUMMARY

Pillitteri, Vera Louise. Screening for Diabetes in At-Risk Populations in Primary Care:
A Practice Guideline. Unpublished Doctor of Nursing Practice capstone project,
University of Northern Colorado, 2017.
Diabetes mellitus (DM), a disease with far-reaching cardiovascular and
physiological consequences, continues to grow at epidemic proportions despite efforts by
the medical community to manage the disease, placing an enormous financial burden on
the healthcare system. The Centers for Disease Control and Prevention released a report
in 2014 reporting 29.1 million people in the United States have diabetes including 8.1
million undiagnosed cases. Colorado is one of eight states with the most significant
increases in DM diagnoses, nearly doubling between 2003 and 2014. An estimated
300,000 adults have diabetes in Colorado and an estimated 110,000 more are
undiagnosed (Colorado Department of Public Health and Environment, 2015).
In the last three years, the American Diabetes Association (ADA; 2017), the
World Health Organization (WHO; 2011b) and the U.S. Preventative Services Task
Force (USPSTF; 2017) have released new recommendations on screening and diagnosing
DM--all with nearly identical criteria; yet, these recommendations are rarely referenced
or utilized. Glycosylated hemoglobin A1c (A1c) and fasting glucose levels are the most
widely recognized tests for screening and managing diabetes and are included in the
screening recommendations for the three largest organizations. To enhance the quality
and consistency of diabetes screening practices in adults in the primary care setting, the
iii

purpose of this capstone project was to create a simple yet comprehensive clinical
practice guideline utilizing fasting glucose levels and A1c as screening tests to aid
providers at Park Avenue Medical Group in Ft. Lupton, Colorado.
Two rounds of Delphi surveys were completed by expert provider participants to
provide the foundation for the development of a clinical practice guideline in conjunction
with current literature supported by the ADA (2017), WHO (2011b), and USPSTF (2017)
and a retrospective study conducted as part of this research project. Five providers
responded to the first round of surveys and four responded to the second round to elicit
over an 80% response rate on the utility, comprehensiveness, and practical use of a
diabetes screening guideline and algorithm. The results indicated a strong need for a
discrete and comprehensive practice guideline.
Data extracted from the retrospective study, literature review, and Delphi surveys
were aggregated to develop the clinical practice guideline; through the use of the second
Delphi survey, the guideline was refined to accommodate the provider participants’
recommendations. In addition to the creation of a written guideline, an algorithm was
designed that offered two clinical pathways depending on age to screen with an informal
risk assessment and A1c at different intervals. Additional recommendations outside the
scope of this capstone project were included to conduct a second post-implementation
retrospective study after an initial pilot period. The Stetler (2001) model was used to
translate the research for this project into practice utilizing a clinical practice guideline.
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CHAPTER I

STATEMENT OF THE PROBLEM

Background and Significance
Diabetes mellitus (DM) is a disease well known to the medical community.
Despite continuous research efforts to manage the disease, it continues to grow at
epidemic proportions, placing enormous financial burdens on the healthcare system. The
National Diabetes Statistics Report released most recently in 2014 by the Centers for
Disease Control and Prevention (CDC), reported 29.1 million people in the United States
have diabetes. Included in that astronomical statistic was 8.1 million undiagnosed cases
(CDC, 2014). An estimated 28.9 million people with diagnosed and undiagnosed DM in
the United States are over the age of 20 and it affects men more than women. American
Indians/Alaska Natives have the statistically highest incidence of all races and ethnicities
at 15.9%, followed by non-Hispanic Blacks (13.2%), Hispanics (12.8%), and Asian
Americans (9.0%); non-Hispanic Whites have the lowest rates at 7.6% (CDC, 2014). In
2012, over 1.7 million people over the age of 20 were newly diagnosed with diabetes and
an estimated 37% or 86 million additional American adults are considered to have
prediabetes based on fasting blood glucose or A1c levels. Two-hundred and eight
thousand individuals under the age of 20 carry a Type 1 or Type 2 DM diagnosis. In the
adolescent population, an estimated 23,525 individuals are diagnosed with Types 1 or 2
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diabetes annually with increased incidence noted in the 10- to 19-year-old age group
(CDC, 2014).
In Colorado, there was a 55% increase in the incidence of DM, identifying the
state as one of eight states with the most significant increase in cases in recent years-growing from 4.7% in 2003 to 7.3% in 2014 (Colorado Department of Public Health and
Environment [CDPHE], 2015). Nearly 20,000 Colorado residents were newly diagnosed
with DM in 2014 alone and over half of the diagnoses occurred in the 18- to 54-year-old
age group. Additionally in Colorado, an estimated 300,000 adults have a diabetes
diagnosis along with an estimated 110,000 more undiagnosed (CDPHE, 2015). Hispanic
and Black individuals are nearly twice as likely to have diabetes compared to White
individuals. As age increases, the prevalence of DM also increases, while education and
socioeconomic status are inversely related to a diabetes diagnosis. Demographically
speaking, southeastern Colorado has the highest diabetes prevalence, which is nearly
twice the state’s average (CDPHE, 2015).
Diabetes is a disorder characterized by a marked elevation of blood glucose levels
resulting from abnormal insulin production. Type 1 diabetes can be diagnosed at any
age; however, it is typically diagnosed in the teens and occurs when the beta cells in the
pancreas are destroyed by mediation or initiation of the body’s immune response. The
end result is limitation or elimination of insulin secretion, causing elevations in glucose
levels. Currently, Type 1 diabetes cannot be prevented and must be treated with insulin
delivery via subcutaneous injection or intrathecal pump at regular intervals (CDC, 2014).
Type 2 diabetes usually develops later in life and accounts for 90-95% of all diabetes
diagnoses. This type of diabetes begins with insulin resistance caused by dysfunction of
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the cells within the muscles, liver, and fat tissues. The beta cells lose their ability to
produce sufficient quantities of insulin, causing a gradual rise in blood glucose levels
over time (CDC, 2014). Age, obesity, family history, physical inactivity, race/ethnicity,
history of impaired glucose metabolism, or gestational diabetes are all risk factors for the
development of Type 2 diabetes. Type 2 diabetes is treated with diet, exercise, and oral
and injectable glucose lowering agents; it may be reversible depending on cause (CDC,
2014). Prediabetes is diagnosed when an individual has elevations in blood glucose or
glycosylated hemoglobin levels but not yet meeting the diagnostic criteria for diabetes.
Prediabetes is the precursor to Type 2 diabetes and carries the same cardiovascular risk;
however, it can be avoided through lifestyle modifications including weight loss, diet,
and exercise (CDC, 2014).
Diabetes is not only a disorder of blood glucose levels. It is a vascular disease
with far reaching and potentially devastating consequences including end-organ failure.
Most affected individuals have one or several comorbidities such as hypertension,
hyperlipidemia, obesity, cardiovascular disease, and kidney disease leading to heart
attack and stroke, blindness, and amputations (CDC, 2014). In addition to the
comorbidities and complications mentioned, people with DM may develop neuropathies,
non-alcoholic fatty liver disease, periodontal disease, hearing loss, and depression.
Diabetes mellitus is the seventh leading cause of death in the United States. It is
suspected to be underreported as the actual cause of death in people with several
comorbidities (CDC, 2014) and is the eighth leading cause of death in Colorado
(CDPHE, 2015). The risk of death among people with diabetes is almost twice as high as
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individuals with similar risk factors who do not have diabetes (Deshpande, Harris-Hayes,
& Schootman, 2008).
Diabetic ketoacidosis (DKA) is a diabetes-related emergency characterized by
hyperglycemia, hyperketonemia, and metabolic acidosis in extremely insulin deficient
individuals. Diabetic ketoacidosis is a major cause of DM related hospitalizations and
can result in death (MacArthur, 2015). Recent studies indicate DKA hospitalizations are
increasing in the United States. From 1996 to 2006, there was a 35% increase in the
number of hospitalizations with DKA as the primary diagnosis (Palmiere, Bardy,
Mangin, & Werner, 2013). Causes of DKA have been attributed to errors in insulin
dosing, undiagnosed DM, alcohol use, illness or infection, trauma, surgery, or steroid use.
Diabetes is often initially diagnosed during a DKA related hospitalization (MacArthur,
2015). It is estimated approximately 15% of all children and 24% of children under five
years of age are not diagnosed with DM until they are in DKA and over one-third of them
had been seen by a doctor at least once prior to receiving diagnosis (MacArthur, 2015).
Diabetic ketoacidosis is the most common cause of death in children and adolescents
with Type 1 diabetes and accounts for half of all deaths in patients under 24 years of age
with DM (Palmiere et al., 2013).
Fulminant diabetes is a new subtype of Type 1 diabetes considered to be
idiopathic in nature. The clinical features include abrupt onset of ketosis or ketoacidosis
and nearly absent C-peptide secretion along with elevated plasma glucose levels and
almost normal HbA1c levels (Imagawa & Hanafusa, 2006). This subset of DM is
especially concerning because of the rapid onset of symptoms and higher potential for
death. Fulminant DM does not fit the usual clinical presentation of Type 1 diabetes
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including childhood onset with elevated HbA1c levels and islet-associated antibodies.
Individuals with fulminant diabetes often present to the emergency department (ED) in
DKA with blood glucose levels over 1000 mg/dL on the day of onset with normal levels
in the days prior to their admission (Imagawa & Hanafusa, 2006). In a Korean study, the
prevalence of fulminant DM in newly diagnosed patients with diabetes was reported to be
7.1% and 30.4% among patients with adult onset diabetes (Palmiere et al., 2013).
Diabetes is an expensive disease, costing the nation over $245 billion in 2012
(CDC, 2014). The average cost per patient per year in Colorado was over $13,000
(CDPHE, 2015). Medical expenditures for diabetes-related treatment is 2.3 times higher
than those without a DM diagnosis (CDPHE, 2015). One in every five healthcare dollars
is directly attributable to diabetes with additional indirect costs associated with
absenteeism, reduced productivity at work (presenteeism), and lost capacity to work
(American Diabetes Association [ADA], 2013). Forty percent of the total amount of
healthcare expenditures related to DM were due to higher hospital admission rates and
longer than average inpatient stays. According to the ADA (2013), this is the single
largest medical cost associated with DM. Diabetic medications account for over a quarter
of diabetes-related healthcare expenditures with the remainder of the costs associated
with diabetes-related health resources, much of which is provided by Medicare. As the
diabetic population ages, the cost per person is expected to increase due to resource
utilization from inpatient, outpatient, skilled nursing facility, and medication usage
(ADA, 2013).
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Problem Statement
Screening for diabetes is currently performed through several methods--most
commonly by fasting plasma glucose levels and glycosylated hemoglobin levels. With
the emergence of recent data, current screening methods would fail to detect DM in a
large population of individuals including at-risk African Americans with low
triglycerides and normal high-density lipoprotein (HDL) and A1c levels, individuals with
hemoglobinopathies, and individuals with unrecognized fulminant diabetes. Still
troubling is the current literature suggesting DM is often unrecognized until a
hospitalization following DKA, often resulting in death.
A study by Corriere, Minang, Sisson, Brancati and Kalyani (2014) addressed the
use of clinical guidelines for decision-making related to diabetes. The authors concluded
only 53% of queried providers used a guideline routinely, suggesting significant gaps
exist in diabetes-related decision-making among providers. Surprisingly, the study
revealed a low level of diabetes- related knowledge among both providers who did and
did not use a clinical guideline routinely. The authors surmised this disparity as one
reason guideline adherence was low. Clinical guideline use is associated with greater
diabetes-related knowledge and essentially better patient outcomes (Corriere et al., 2014).
The purpose of this capstone project was to develop a simplistic clinical practice
guideline to screen for DM in a primary care setting in an effort to facilitate early
detection and initiate treatment to minimize diabetes-related complications and mortality
in those individuals at highest risk.
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The following research question guided this capstone project:
Q1

In a primary care setting, how does guideline implementation to screen for
diabetes mellitus compared to traditional screening techniques influence
early detection in patients with previously undiagnosed diabetes?
Theoretical Framework

The high incidence of undiagnosed and underdiagnosed diabetes mellitus in the
United States and locally in Colorado and the current methodology used to screen for
diabetes demonstrate a lack of knowledge of significant risk factors beyond elevated
glycosylated hemoglobin and plasma glucose levels in the primary care setting.
Translating current research into practice is a necessary step to decreasing the morbidity
and mortality related to diabetes or pre-diabetes diagnoses. The Stetler (2001) model,
originally developed in 1976, uses a step-wise, practitioner-oriented approach to research
utilization by converting knowledge into practice through five phases: preparation,
validation, comparative evaluation/decision making, translation/application, and
evaluation.
Phase I: Preparation
The preparation phase of the Stetler (2001) model addresses the purpose, context
and sources of research evidence. During this phase, the purpose of the capstone project
was acknowledged and internal and external factors were addressed. The perceived
problems were identified and prioritized and the research design was determined.
Measurable outcomes were organized and Institutional Review Board (IRB) approval
was obtained through the University of Northern Colorado prior to project
implementation (see Appendix A).
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Phase II: Validation
The purpose of this phase was to focus on the utilization of the sources of
evidence. Within this phase, a comprehensive, systematic literature review was
performed that identified the strength of the evidence presented in the project. Resources
were reassessed to address their applicability to improve current practices and noncredible sources were eliminated. A project without sufficient credible evidence would
have been terminated during this phase of the Stetler (2001) model.
Phase III: Comparative Evaluation/
Decision Making
During Phase III of the Stetler (2001) model, the findings of the literature review
were synthesized by identifying similarities and differences and an evaluation of the
degree of evidence substantiation. A decision was made about which evidence would be
utilized for the capstone project (Stetler, 2001).
Phase IV: Translation/Application
The translation of the synthesized findings (recommendations) into practice was
the focus of Phase IV (Stetler, 2001). For the purposes of this project, a guideline was
created using the data extracted from a retrospective chart review and the literature
review. The plan to disseminate the guideline was formalized during this phase and
entailed providing the new clinical guideline to the providers at Park Avenue Medical
Group (PAMG).
Phase V: Evaluation
Evaluation is the final phase of the Stetler (2001) model. A formal appraisal of
the clinical guideline implementation was evaluated for credibility, goal progress, and
results. Changes and recommendations were provided as considerations for future
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studies (Stetler, 2001). Phase V also appraised any unexpected or negative outcomes. A
cost-benefit analysis would be performed during this phase of the Stetler model;
however, post-implementation evaluations were not conducted in this capstone project
due to time constraints. Figure 1 provides a visual representation of the Stetler model.

Figure 1. The Stetler model: Phases of research utilization to facilitate evidence-based
practice.

Literature Review
The literature review was conducted to evaluate current diagnostic standards
published by the ADA (2017), the U.S. Preventative Services Task Force (USPSTF;
2017), and the World Health Organization (WHO; 2016). The purpose of the
investigation was to (a) evaluate gaps in diagnosis criteria utilized by three of the largest
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research-based organizations with published diagnostic guidelines for diabetes and (b)
establish congruency in diagnostic and screening techniques. The following electronic
databases were utilized for the literature review: the Cochrane Database Systematic
Review, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Google
Scholar, and PubMed. Keywords included in the search were diabetes guidelines,
diabetes in primary care, clinical guidelines, diabetes management, diabetes screening,
screening criteria and diabetes diagnosis. Criteria included full text articles published
between 2009 and 2017 and written in the English language. Study types were
systematic reviews, meta-analysis, cohort studies, and randomized controlled studies.
American Diabetes Association
Guidelines
The American Diabetes Association (Cefalu, 2017) released their 2017 Standards
of Medical Care in January based on current literature and evidence-based practice (see
Table 1). Attempting to uphold the highest standards, the majority of their
recommendations were based on A- or B-level evidence. A-level evidence is derived
from clear evidence from randomized controlled trials (RCT), compelling
nonexperimental evidence, or supportive evidence from RCTs. B-level evidence is
derived from supportive evidence from cohort studies (Cefalu, 2017).
The ADA (Cefalu, 2017) recommended several diagnostic tests for diabetes and
prediabetes using fasting plasma glucose levels (FPG) or the two-hour plasma glucose
value after a 75-gram oral glucose tolerance test or the glycosylated hemoglobin A1c
criteria--all are equally appropriate for diagnostic testing (Cefalu, 2017, p. S12).
Compared to A1c and FPG values, the two-hour plasma glucose value is predictive of
more people with diabetes. A1c levels have a convenience advantage over the other two
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plasma glucose values and is less influenced by stress and illness--known precursors to
skewed glucose levels; however, it is less sensitive and costlier to perform (Cefalu,
2017).

Table 1
American Diabetes Association Diagnostic Criteria for Diabetes
Test

Value

Description

Fasting Plasma Glucose

≥ 126 mg/dL

Fasting is defined as no caloric
intake for > 8 hours

Two-hour Plasma Glucose

≥ 200 mg/dL

Using WHO guidelines and glucose
load of at least 75 g of anhydrous
glucose

A1c

≥ 6.5%

Lab tested using method that is
NGSP certified and standardized

Random Plasma Glucose

≥ 200 mg/dL

With classic symptoms of
hyperglycemia
Note. Repeat testing recommended unless clear clinical diagnosis present.

Using the A1c level as a diagnostic tool, the ADA (Cefalu, 2017) recommends
other factors also be taken into consideration. The studies used to determine the A1c
recommendations were based solely on adult populations; it is unknown if the same cutpoint should be used to diagnose DM in adolescents and children (Cefalu, 2017).
Additionally, A1c levels may vary depending on race and ethnicity. African Americans
often have higher A1c levels than Caucasians after similar fasting and post glucose load
levels, suggesting a higher postprandial glycemic burden (Cefalu, 2017). Hemoglobin
A1c levels might also be skewed in patients with abnormal red blood cell turnover or
hemoglobinopathies such as pregnancy, sickle cell trait, hemodialysis, recent transfusion,
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or erythropoietin therapy, suggesting interpretation of A1c levels in these individuals
would be challenging. Plasma blood glucose criteria should be used to diagnose DM in
patients with abnormal red blood cell turnover (Cefalu, 2017). The diagnosis of diabetes
is made only after repeat confirmation unless there is a clear clinical diagnosis of random
plasma glucose level ≥ 200 mg/dL in a symptomatic individual. The second test should
be conducted as soon as possible and questionable results should be repeated in 3-6
months (Cefalu, 2017).
Screening for diabetes is recommended in overweight or obese adults with one or
more risk factors including A1c level ≥ 5.7%, impaired glucose tolerance (IGT) test,
impaired fasting glucose (IFG) levels, a first-degree relative with DM, high risk ethnicity,
women with past history of gestational diabetes, history of cardiovascular disease or
hypertension, women with polycystic ovarian syndrome or other diseases causing insulin
resistance, or physical inactivity. The ADA (Cefalu, 2017) recommends routine testing
for everyone beginning at age 45 and repeated every three years for individuals with
normal results. More frequent testing is recommended based on risk stratification and
prediabetes status (Cefalu, 2017). Children and adolescents who are overweight or obese
and have at least two additional risk factors should also be tested for prediabetes using
FPG, two-hour plasma glucose or A1c levels. The ADA’s Expert Committee on the
Diagnosis and Classification of Diabetes Mellitus defined a confirmed diabetes diagnosis
if fasting or impaired plasma glucose levels were between 100 and 125 mg/dL. This
differs from the World Health Organization’s cutoff at 110 mg/dL (Cefalu, 2017).
The ADA (Cefalu, 2017) recommends Type 1 diabetes, also called immunemediated diabetes, be diagnosed using blood glucose levels rather than A1c.
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Additionally, antibody screening is recommended in research trials or if a first-degree
relative has Type 1 diabetes. Type 1 DM is often diagnosed after a hyperglycemic crisis
or life-threatening DKA. It has been suggested that measuring islet antibodies in
relatives of those affected by Type 1 DM might help identify individuals at risk for
developing Type 1 diabetes before a hyperglycemic crisis or DKA event. Type 2
diabetes is much more insidious and frequently goes undiagnosed for several years. The
overall risk of developing cardiovascular complications is the same in undiagnosed as in
diagnosed DM (Cefalu, 2017).
A diagnosis of prediabetes is instrumental in the prevention or delay of Type 2
diabetes. The ADA (Cefalu, 2017) recommends yearly monitoring for the development
of DM in individuals with a prediabetes diagnosis and intensive behavioral modifications
to achieve and maintain a loss of 7% of initial body weight. Additionally, the ADA
recommends 150 minutes per week of moderate intensity physical activity augmented by
technology assisted tools such as fitness applications, social networks, mobile diet
tracking, and DVD-based content related to lifestyle modifications (Cefalu, 2017). The
diabetes prevention program (DPP) is an intensive lifestyle modification program,
demonstrating a reduction in the incidence of Type 2 diabetes by 58% over three years by
implementing the 7% weight reduction and 150 minutes per week of moderate intensity
activities. This is by far the strongest evidence presented in the prevention of Type 2 DM
with numerous studies demonstrating sustained reduction in the conversion rate to DM
(Cefalu, 2017).
Studies have demonstrated that reduction of caloric intake through quality of fat
consumption rather than quantity has been contributory in preventing or delaying the
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onset of Type 2 DM. The Mediterranean diet--whole grains, nuts, berries, coffee, tea and
yogurt--includes food items known to prevent Type 2 diabetes and are effective at
lowering A1c levels (Cefalu, 2017). Moderate intensity physical activity such as brisk
walking improves insulin sensitivity and reduces abdominal fat in young adults and
children. Resistance training and breaking up prolonged sedentary time by walking has
shown to moderately lower postprandial glucose levels in addition to reducing the risk of
the development of gestational diabetes (Cefalu, 2017). Pharmacologic interventions for
diabetes prevention include oral glucose lowering agents such as metformin,
pioglitazone, and exenatide, with metformin demonstrating the strongest evidence for
long-term safety and efficacy. Lifestyle modification and DPP were more effective than
metformin but were costlier over a 10-year period (Cefalu, 2017).
Medications used in the treatment of diabetes include insulin for Type 1 diabetes
and various oral and injectable agents for the treatment of Type 2 DM. Initial therapy in
Type 2 DM should include monotherapy with metformin unless the A1c is greater than
9% in which dual therapy in indicated. With individuals with blood glucose levels
greater than 300 or A1c greater than 10%, combination injectable therapy is
recommended. A1c levels are checked at regular three- to six-month intervals and a
stepwise approach to pharmacologic management is utilized until target A1c levels are
met (Cefalu, 2017).
World Health Organization
Guidelines
The WHO (2016) released new recommendations for the screening and diagnosis
of diabetes after conducting their own systematic review of international literature
available on the subject (see Table 2). While the ADA’s (Cefalu, 2017)
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recommendations seemed to mirror the WHO guidelines, several key points were
emphasized in the WHO report. Specifically, the WHO report analyzed the usefulness of
the hemoglobin A1c as a diagnostic tool for the detection of Type 2 diabetes in the world
population. Currently, the WHO does not endorse the use of the HbA1c for the diagnosis
of diabetes due to the limited availability of the test in many countries, its influence on
hemoglobinopathies, and global inconsistencies in the A1c measurement (WHO, 2011b).

Table 2
World Health Organization’s Recommendations on Diagnostic Criteria for Diabetes
Test
Fasting Plasma Glucose

Value
≥ 7.0 mmol/L (126 mg/dl)

Two-hour Plasma Glucose

≥ 11.1 mmol/L (200 mg/dl)

HbA1c

≥ 6.5%

Note. Adapted from The World Health Organizations Diabetes Recommendations (2016).

The WHO (2016) guidelines, similar to the ADA’s (Cefalu, 2017) guidelines,
based their recommendations on the quality of evidence using the grading of
recommendations, assessment, development and evaluation (GRADE) methodology;
however, feasibility and resources for low and middle-income countries were also
considered. The strength of the recommendations was based on a 2-point scale.
Weak/conditional recommendations had a low, moderate, or high quality of evidence but
were not applicable in lower resource countries. Strong recommendations were moderate
or high quality of evidence and were applicable in low resource settings (WHO, 2016).
The WHO concluded the A1c level could be used as a diagnostic test for diabetes only if

16
stringent quality assurance processes were in place based on moderate GRADE quality of
evidence and conditional strength of recommendations. The A1c cut point for a diabetes
diagnosis was 6.5%. Unlike the ADA’s recommendations, the WHO concluded there
was insufficient evidence to make any recommendations on A1c levels below 6.5%
(WHO, 2011a).
The WHO’s (2016) recommendations included a statement regarding the
diagnosis of DM in an asymptomatic individual. The diagnosis should not be based on a
single abnormal plasma glucose or A1c level. A second test with values within the
diabetic range is required for diagnosis according to WHO standards, using fasting,
random, or oral glucose tolerance testing in a stringently controlled testing or lab
environment. Use of the same diagnostic test is recommended; however, if a different
test is utilized, the results could be used to formalize a diabetes diagnosis. Periodic
retesting is recommended for individuals having a singular positive diagnostic test and
negative second test until DM status is clear (WHO, 2016).
U.S. Preventative Services Task Force
Recommendations
The U.S. Preventative Services Task Force (Siu, 2015) released their latest
recommendations on screening for Type 2 diabetes in December 2015 (see Table 3).
Their recommendations pertained to the adult population ages 40-70 who are overweight
or obese and asymptomatic. Like the ADA and WHO recommendations, the USPSTF’s
recommendations are based on the level of evidence but do not consider the cost of
providing the screening services to the public (Siu, 2015). The USPSTF (2017)
guidelines are based on grade B recommendations, suggesting high to moderate certainty
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of beneficial health outcomes from the implementation of their guidelines (USPSTF,
2017).

Table 3
U.S. Preventative Services Task Force Diagnostic Criteria for Type 2 Diabetes
Test

Value

Hemoglobin A1c Level

≥ 6.5%

Fasting Plasma Glucose Level

≥ 7.0 mmol/L
≥ 126 mg/dl

2-hour Oral Glucose Tolerance Test

≥ 11.1 mmol/L
≥ 200 mg/dl

Note. Adapted from Siu (2015).

The USPSTF (Siu, 2015) recommendations to screen only adult patients ages 4070 who are asymptomatic and overweight or obese were based on their research,
indicating the target population is at the highest risk for cardiovascular complications
related to a diabetes diagnosis and would reap the most benefit from primary prevention
through intensive risk factor modification. Furthermore, the USPSTF acknowledged
persons with additional risk factors such as family history of diabetes, history of
gestational diabetes, polycystic ovarian syndrome, or persons of high risk ethnicities
might be at risk for developing diabetes at a younger age or with a lower body mass
index (BMI), and therefore recommend screening earlier for individuals with at least one
of these risk factors (Siu, 2015).
Screening tests recommended by the USPSTF (Siu, 2015) included the HbA1c,
fasting plasma glucose level, or the oral glucose tolerance test. Like the
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recommendations of the ADA and WHO, the USPSTF recommended repeat testing with
the same test on a different day to confirm a diabetes diagnosis. Screening intervals for
individuals with an initial normal glucose level is recommended every three years (Siu,
2015). The USPSTF additionally recommended performing an annual risk assessment to
identify risk factors for abnormal glucose metabolism such as obesity, physical inactivity,
smoking, hypertension, and hyperlipidemia; however, no recommendations were offered
on screening individuals with multiple risk factors (Siu, 2015).
Based on the evidence collected by the USPSTF (Siu, 2015), intensive behavioral
counseling interventions for individuals at increased risk for cardiovascular disease are
beneficial for lowering overall cardiovascular risk. These interventions are especially
helpful in populations with hypertension, hyperlipidemia, and obesity, demonstrating a
reduction in the specific risk factor values. Interventions aimed at individuals with
impaired fasting glucose levels or impaired glucose tolerance could prevent diabetic
conversion. Lifestyle interventions are more effective at reducing progression to diabetes
than medications such as metformin (Siu, 2015).
The USPSTF (Siu, 2015) recommended sending patients with a BMI > 25 and
additional cardiovascular risk factors to intensive behavioral counseling to promote
cardiovascular health through healthy diet training and exercise programs. Screening for
lipid disorders should begin in men over the age of 35 and women over the age of 45,
who also have an increased risk for heart disease. Screening for hypertension should
begin at age 18 and tobacco use assessed annually with cessation interventions offered as
needed (Siu, 2015).
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Comparison of the Three Organization’s
Modalities and Other Considerations
Clinical guidelines are intended to assist providers in the diagnosis and
management of illness and disease processes. The increased prevalence of diabetes,
especially Type 2 diabetes, has created an urgent need for uniformity in the diagnosis and
management of the disease. Although the ADA (Cefalu, 2017), WHO (2016), and
USPSTF (Siu, 2015) have minor and negligible differences in the diagnosis techniques
for diabetes, all agreed early diagnosis and treatment minimize the cardiovascular
complications of later stages of the disease. A meta-analysis and systematic review by
Khunti et al. (2015) evaluated screening methods for the diagnosis of Type 2 diabetes by
examining response rates, positive outcomes at initial and intermediate screening stages,
and yield rates using 1-step, 2-step, and 3-4 step processes. Initial response rates were
defined as the proportion of people who accepted the invitation to the screening study
compared to the total number invited. The yield rate was the number of newly diagnosed
Type 2 diabetes cases compared to the total number screened using the oral glucose
tolerance test (OGTT) or blood test. Invasive versus non-invasive testing methods were
evaluated for heterogeneity and sensitivity (Khunti et al., 2015).
The findings from the Khunti et al. (2015) study indicated the number needed to
detect a single case of diabetes using the OGTT (1-step process) decreased as the number
of steps increased. The 2-step screening strategies, where test subjects were screened for
diabetes prior to the OGTT, had a higher initial response rate and yet there was no change
in yield and response rates if a blood test was used as the initial screening step (Khunti et
al., 2015). Conversely, considering all methods, the number of individuals at high risk
for diabetes or diagnosed with diabetes decreased as the number of steps in the diagnosis
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process increased, indicating less people needed to have the OGTT when screening and
retesting were used. Khunti et al.’s meta-analysis was unable to compare screening
strategies such as the HbA1c and random or fasting blood glucose levels utilized in the 2step and 3-4 step processes due to a lack of available qualified studies, suggesting a study
limitation or identified area for further investigation.
A similar study by Bowen, Xuan, Lingvay, and Halm (2017) evaluated the
sensitivity and specificity of the ADA, WHO, and USPSTF guidelines. Over 7,100
participants met study criteria. Seventy-eight percent of participants met the screening
criteria using the ADA guidelines, 24% met the USPSTF screening guidelines, and 34%
met the latest USPSTF screening guidelines (Bowen et al., 2017). Bowen et al.’s study
reported the ADA guideline’s sensitivity to detect undiagnosed diabetes was 99.2%;
however, their specificity was only 23%, causing a 78% false positive rate. The
USPSTF’s guideline criteria had a 76.7% specificity rate and 41.9% sensitivity rate while
the WHO guideline had a 67% specificity rate and 65% sensitivity rate (Bowen et al.,
2017).
The results of the Bowen et al. (2017) study suggested screening all participants
with a random blood glucose level ≥ 100 mg/dL would screen an additional 23% of
adults in the sample. This statistic was based on literature suggesting a single random
glucose level ≥ 100mg/dL was more predictive of undiagnosed DM than traditional risk
factors (Bowen et al., 2017). Identifying individuals with higher risk for the development
of diabetes could be achieved by lower random glucose cut points creating higher
sensitivity while higher cut points would create greater specificity. Utilizing a random
glucose level ≥ 100 mg/dL would achieve balanced sensitivity and specificity in detecting

21
undiagnosed DM. A case-finding strategy was utilized to identify individuals with a
random glucose level ≥ 100mg/dL; the authors concluded it would screen half as many
people as the ADA and USPSTF guidelines to correctly identify one person with
undiagnosed diabetes, thus maximizing case yield and minimizing unnecessary screening
costs (Bowen et al., 2017).
Summary of a Systematic Review Using
the U.S. Preventative Services Task
Force Screening Guideline
Selph et al. (2015) performed a systematic review of RCT, controlled trials,
observational studies, and screening methods for Type 2 diabetes using the USPSTF
recommendations to determine if health outcomes were improved in individuals with
impaired fasting glucose levels or impaired glucose tolerance through screening and early
intervention. The meta-analysis of the selected studies discussed the results of several
key factors. Benefits of screening for diabetes versus no screening were evaluated to
assess long-term cardiovascular mortality and all-cause mortality over 10 years,
concluding screening was not associated with better outcomes or reduced cardiovascular
mortality. Similarly, screening did not reduce the risk for all-cause mortality in the
studies surveyed. The harms of screening were also evaluated, demonstrating increased
short-term anxiety in the initial six weeks post screening for a new diagnosis of diabetes
and no negative psychological effects after one year (Selph et al., 2015).
Studies evaluating the treatment of USPSTF screen-detected IFG or IGT or early
diabetes included in the systematic review suggested split support on the validity of
lifestyle interventions for all-cause or cardiovascular risk reduction (Selph et al., 2015).
One study out of China concluded a six-year lifestyle intervention was associated with
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risk reduction in both categories after 23 years of follow-up, while other lifestyle
intervention trials demonstrated no beneficial outcomes on all-cause or cardiovascular
mortality (Selph et al., 2015). Pharmacological interventions were also considered for
USPSTF screened individuals with new onset diabetes of IGT or IFG levels with studies
demonstrating few benefits or reduction in mortality rates from trials of glucose lowering
agents over placebo (Selph et al., 2015). Studies evaluating the harms associated with
treating screen detected diabetes or IFG or IGT were reviewed, suggesting that compared
to placebo, interventions could result in harm and included complications such as
hypotension, hypoglycemia, withdrawal symptoms, and increased incidence of
congestive heart failure (Selph et al., 2015).
Intensive treatment options versus standard treatment were also evaluated in the
systematic review, concluding no risk reduction with intensive treatment for a first fatal
or non-fatal cardiovascular event; however, all-mortality and cardiovascular event rates
were lower (Selph et al., 2015). Intensive glucose lowering therapy was associated with
risk reduction for non-fatal myocardial infarctions; yet management including goal
HgbA1c levels between 6.0% and 7.5% resulted in no decrease for all-cause or
cardiovascular mortality compared to less intensive methods of management (Selph et al.,
2015). Intensive blood pressure management decreased risk for all-cause mortality
according to one study but differing definitions of intensive therapy caused the trial to
lose validity. More recent studies evaluated in the systematic review suggested similar
results with consistent risk reduction in all-cause and cardiovascular mortality when an
angiotensin-converting enzyme inhibitor and diuretic were added (Selph et al., 2015).
Harms caused by intensive treatment versus standard treatment were also considered in
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the review, demonstrating low and imprecise rates of reported harm with multifactorial
treatment. Intensive glucose lowering treatments were associated with higher rates of
hypoglycemia and other medication-related adverse events requiring hospitalization
(Selph et al., 2015).
The benefits of treating impaired fasting glucose and impaired glucose tolerance
levels to delay or prevent conversion to diabetes were also evaluated in the systematic
review (Selph et al., 2015). The studies evaluated lifestyle and pharmacological and
multifactorial interventions over six months to six years. Lifestyle interventions were
associated with decreased risk of conversion to a diabetes diagnosis in six of the studies
reviewed. Pharmacological interventions indicated thiazolinediones decreased
progression to diabetes as well as combinations of valsartan and low dose metformin and
rosiglitazone (Selph et al., 2015). Nateglinide and glimepiride were not associated with
risk reduction for progression to diabetes. Multifactorial approaches to prevent
progression included glucose, blood pressure (BP), and lipid control in addition to
lifestyle modifications; aspirin demonstrated a statistically significant decrease in the
progression to diabetes in several of the studies evaluated in the systematic review (Selph
et al., 2015).
Diabetes Guidelines in Clinical Practice
Underutilization of diabetes guidelines in the primary care setting is challenging
and multifactorial. According to Bouchonville, Matani, DuBroff, and DuBroff (2017),
published guidelines often exclude relevant studies or are not evidence-based, causing
confusion and discord in diabetes management and leading to low provider adherence.
Bouchonville et al.’s study evaluated studies that target traditional cardiovascular risk
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factors in diabetic patients: anti-platelet therapy, blood pressure, glycemic and lipid
control, and lifestyle interventions. The results of their systematic review suggested the
ADA’s recommendations regarding a Mediterranean diet, blood pressure, and glycemic
control were truly evidence-based but had questionable evidence to support specific
pharmacological therapies. Additionally, the review suggested the ADA’s evidence to
support the use of aspirin or other anti-platelet therapy or statins in the management of
diabetes was inconsistent and contradictory (Bouchonville et al., 2017). While
Bouchonville et al.’s systematic review did not specifically pertain to the utilization of
guidelines to screen and diagnose diabetes, it highlighted the confusion providers face in
diabetes prevention, screening, and management. A second systematic review (De
Belvis, Pelone, Biasco, Ricciardi, & Volpe, 2009) evaluating diabetes management
guidelines surveyed over 1,700 abstracts and found only 13 articles suitable for their
review and only one discussed guideline application and outcome/process indicators to
evaluate delivery and adherence to evidence-based guidelines. To aid providers in sifting
through the abundance of literature, De Belvis et al. (2009) suggested educational/
training interventions, interactive technology, audit interventions or a combination of
interventions to promote uniformity in diabetes management.
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CHAPTER II

PROJECT DESCRIPTION

Project Objectives
The primary care setting is ideal for preventative health care, especially screening
for diabetes and other diseases of chronicity. Annual preventative or wellness visits are
covered by nearly all health insurance plans and provide the opportunity to screen for
diseases with far-reaching, end-organ, and cardiovascular consequences like diabetes.
Recent changes in diabetes screening guidelines, lack of utilization, and absence of
consensus on current screening practices provided an opportunity to intervene and create
a clinical practice guideline to detect diabetes earlier in the primary care setting with the
intention to screen individuals at the greatest risk or highest likelihood of reversibility
through early diagnosis and treatment.
The following four objectives for this capstone project included the creation of a
diabetes screening clinical practice guideline to support congruency in screening
practices based on the latest evidence-based literature:
1.

Gather information on current diabetes screening practices for the adult
population at Park Avenue Medical Group. The information was collected
through a retrospective chart review evaluating screening processes and risk
stratification for adult patients over the age of 25 seen in the clinic for
wellness/preventative visits.
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2.

Survey a panel of expert providers within and outside Park Avenue Medical
Group to assess gaps in screening processes and willingness to adopt a new
diabetes screening guideline.

3.

Develop a diabetes screening guideline for providers to utilize during
routine annual wellness visits based on the literature and consensus obtained
through the survey.

4.

Due to time constraints, this capstone project did not implement the clinical
practice guideline.
Project Plan

Setting
The setting for this capstone project was Park Avenue Medical Group (PAMG) in
Fort Lupton, Colorado. Park Avenue Medical Group is a small, privately owned practice
comprised of one physician and one nurse practitioner providing services including acute
and primary care; well examinations for men, women, and children; sports and
Department of Transportation physicals; immunizations; minor surgeries; and
laboratory/diagnostic testing. Data from a retrospective chart review were gathered from
the practice’s electronic medical record (EMR) from January of 2015 through June of
2017.
Sample
The sample population investigated for the retrospective portion of this project
included adult males and females between the ages of 25 and 60 who visited PAMG for
wellness visits from January of 2015 through June of 2017.
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Resources
As part of the fulfillment of the degree of Doctor of Nursing Practice (DNP),
financial resources were not considered for this capstone project. The retrospective study
portion of the project was completed by this researcher utilizing PAMG’s electronic
medical record.
Phases
Phase one. The first phase of this evidence-based capstone project entailed the
completion of a thorough literature review. The results of the literature review indicated
a strong need for congruency and compliance to a clinical practice guideline to aid
providers in screening for diabetes in the primary care setting. Included in phase one was
the retrospective chart review, which was intended to extract data from the specified
sample population. Each chart reviewed was evaluated for ADA (Cefalu, 2017), WHO
(2016), and USPSTF (Siu, 2015) risk factors, if screening was performed and the results,
and for glucose levels over 100 mg/dL to improve sensitivity and specificity of the
screening process. In total, 709 charts were reviewed and 424 met all inclusion criteria.
Phase two. The second phase of the project was to create an evidence-based
practice guideline. The Delphi method was utilized to survey a panel of clinical experts.
Data extrapolated from the survey were compiled and the researcher collaborated with
the expert panel to develop the practice guideline. Primary care providers for the expert
panel included two physicians, two nurse practitioners, and one physician’s assistant
within PAMG and in other practices outside of their organization. Responses from the
first Delphi survey questions in phase one helped identify methods currently utilized in
primary care to screen for diabetes, risk factors identified by the providers, what
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guidelines and recommendations were utilized, and specific tests performed in the
screening process.
Phase three. During this phase, the clinical practice guideline was presented to
the providers to review and modify. Providers were educated on how to use the guideline
and the guideline was evaluated using a second round of the Delphi method for proper
utilization and compliance. To promote consistency and preserve the integrity of the
project, the same panel of five expert provider participants from round one of the Delphi
survey was invited to participate in round two. Four of the five providers completed
round two of the survey. The guideline was evaluated during this phase to ensure
objectives were met.
Phase four. This phase entailed the physical implementation of the clinical
guideline. The guideline was provided to PAMG for utilization. As previously stated,
beyond presenting the guideline to the providers at PAMG, this phase was not completed
during this capstone project.
Project Timeline
The researcher utilized the following timeline for project phases:
•

Approval of phenomenon of interest--Fall 2016

•

Defend proposal (Chapters I-III of project) and obtain Institutional Review
Board approvals from University of Northern Colorado (see Appendix A) and
PAMG (see Appendix B)—June-July 2017

•

Retrospective chart review, initial Delphi survey and consent form sent (see
Appendix C), and summary and responses (see Appendix D)—AugustOctober 2017
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•

Development of clinical practice guideline and plan for implementation,
second Delphi survey (see Appendix E), summary and responses (see
Appendix F), finalize Screening for Type 2 Diabetes in Adults Guideline and
Algorithm (see Appendix G), final defense of capstone project, and
submission of completed capstone project to University of Northern
Colorado—October-November 2017
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CHAPTER III

EVALUATION OF PLAN

In an effort to preserve consistency and integrity of this capstone project, each
phase was evaluated through the following four objectives.
Objective One
The first objective was to gather information regarding screening practices for
diabetes in the primary care setting. This objective was accomplished through a
retrospective chart review to evaluate current screening practices at PAMG on adult
patients presenting in the clinic for wellness exams. The data were analyzed for
screening methods and risk stratification in diabetic and non-diabetic patients.
Objective Two
Objective number two was completed by surveying a panel of experts using the
Delphi method to gather information on the utility of a clinical practice guideline. The
panel consisting of practicing physicians, nurse practitioners, and physician’s assistants
was queried about current methods used for screening purposes, suggestions, and general
knowledge to develop a provider friendly, evidence-based practice guideline.
Objective Three
The third objective was the development of the clinical guideline. Information
gathered from the review of evidence (literature review), retrospective chart reviews, and
expert opinions were used to formulate the practice guideline. Since the guideline was
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intended to be utilized, special attention was paid to the consensus of expert opinions to
achieve 70% consensus amongst the providers. The panel of expert providers played an
essential role in the development of the guideline by providing feedback on the feasibility
and utility of the guideline. A second Delphi survey was provided to the panel of experts
once the guideline was completed; revisions were made to accommodate the 70%
consensus goal on provider practices.
Objective Four
The fourth objective was the plan for implementation. Physical implementation
was not part of this capstone project; however, the staff at PAMG were trained on how to
use the clinical practice guideline. If the providers decided to use the practice guideline,
it was recommended that a second retrospective chart review be performed to evaluate
pre- and post-implementation results and make improvements as evidence changed or
was clinically necessary.
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CHAPTER IV

RESULTS AND OUTCOMES

The purpose of this DNP capstone project was to evaluate current diabetes
screening practices in the primary care setting and develop a clinical practice guideline to
promote early detection and treatment of diabetes, thus minimizing long-term
consequences and end organ damage caused by unrecognized and untreated DM. The
first objective of this project was to gather information regarding screening practices for
diabetes in the primary care setting through a retrospective chart review on adult patients
between the ages of 25 and 60 who presented to PAMG for annual wellness exams from
January 2015 through June 2017. Specifically, objective one was evaluating screening
practices and risk stratification in both diabetic and non-diabetic patients. Objective two
utilized the Delphi method to survey a panel of experts in family medicine about current
screening practices and the practical utility of an evidence-based clinical practice
guideline. Objective three included the development of a clinical guideline using
information gathered from the review of evidence, retrospective chart review, and expert
opinion. A second Delphi questionnaire was administered to the panel of experts to
complete this objective, which sought 70% consensus on the clinical utility and
practicality of the guideline. The fourth and final objective was the plan for
implementation. The physical implementation of the clinical guideline was not included
in this capstone project; thus, no formal evaluation was included in the final project.
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Objective One
Objective one was accomplished through a retrospective chart review conducted
to evaluate data on adult patients between the ages of 25 and 60 who presented at PAMG
for wellness exams during the period beginning January 1, 2015 and ending on June 30,
2017. The data were examined to quantify the number of diabetes-related risk factors in
the patient population as well as analyze screening methods used for a wellness visit in
diabetic and non-diabetic patients. Candidates included in the chart review were either
male or female from all races and ethnic backgrounds who presented to the clinic for a
wellness physical where the International Classification of Disease (ICD) 10 code Z00.00
(encounter for general adult examination without abnormal findings) or Z00.01
(encounter for general adult examination with abnormal findings) was used (NuMed
ICD-10 Lookup, n.d.). To be included in the chart review, the patient must also have
completed routine annual blood work ordered by the provider specifically in conjunction
with the wellness visit. Included blood work must have been completed within 30 days
pre- or post-wellness visit and consist of at least a basic metabolic panel with an
identified random or fasting glucose level.
Materials and Methods
Objective one was completed using the Aprima EMR application currently
utilized by PAMG associates and providers. Historical charts were reviewed beginning
on January 1, 2015 and ending on June 30, 2017 on all patients presenting to the clinic
for a wellness visit. Charts on patients outside the ages of 25-60 or without routine
wellness blood work consisting of a basic metabolic panel with a fasting or random
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glucose level were eliminated from the study. In total, 709 charts were reviewed; 285
charts were eliminated, leaving 424 charts meeting all inclusion criteria.
Each patient chart reviewed was assigned a unique identification number and was
analyzed to document ADA (2017), WHO (2011b), and USPSTF (2017) diabetes-related
risk factors including age, gender, ethnicity, body mass index, fasting or random glucose
levels, hemoglobin A1c if available, history of diabetes, gestational diabetes, polycystic
ovarian syndrome, cardiovascular disease, hypertension, and hyperlipidemia. Initial data
included all patients over the age of 25 meeting the aforementioned criteria; patients over
the age of 60 were later omitted prior to the data analysis and were not included in any of
the result statistics.
Results
The results analysis of the chart review reflected a total of 424 patients who
visited PAMG for a physical during the selected time frame. Of the 424 patients, 169
were male (39.86%) and 255 were female (60.14%; see Figure 2). The ethnic makeup of
the selected patient population was derived from demographic information documented
in the patient chart and included 318 White patients (75%), 101 Hispanic patients
(23.82%), two Black patients (0.005%), and three Asian or Pacific Islander patients
(0.007%; see Figure 3). A total of 55 patients (12.97%) had a history of diabetes and 369
patients (87.03%) had no recorded history of diabetes in their medical records (see
Figures 4, 5, and 6). Considering the risk factors identified by the ADA (2017), WHO
(2011b), and USPSTF (2017), 78 patients (18.4%) had a BMI less than 25, indicating
ideal or low body weight; 138 (32.55%) had a BMI between 25 and 29.9, falling in the
overweight range; and 208 (49.05%) had a BMI falling in the obese range (see Figures 7
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and 8). One hundred patients or 23.58% of the queried patient population had a
documented history of hypertension. Two patients (0.005%) had a history of
cardiovascular disease and 131 patients (30.9%) had a history of hyperlipidemia. Of
gender-specific risk factors, polycystic ovarian syndrome and gestational diabetes, only
one patient was documented to have polycystic ovarian syndrome in their history,
accounting for 0.002% of the total surveyed patient population.

GENDER
2017

39

52

64

66

NUMBER OF PATIENTS

103

2016

100

2015

MALE

FEMALE

Figure 2. Gender of surveyed population at Park Avenue Medical Group designated by
year.
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RACE/ETHNICITY
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2

0

0

2
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35

37

62

NUMBER OF PATIENTS

125

2015

ASIAN/PACIFIC
ISLANDER
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Figure 3. Racial and ethnic composition of surveyed population at Park Avenue Medical
Group designated by year.

2015
22

144

Number of Patients with a Documented Pre-Diabetes/Diabetes Diagnosis
Number of Patients Without a Documented Pre-Diabetes/Diabetes Diagnosis

Figure 4. Surveyed patients with a documented pre-diabetes or diabetes diagnosis versus
ones without for 2015.
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2016
22

145

Number of Patients with a Documented Pre-Diabetes/Diabetes Diagnosis
Number of Patients Without a Documented Pre-Diabetes/Diabetes Diagnosis

Figure 5. Surveyed patients with a documented pre-diabetes or diabetes diagnosis versus
ones without for 2016.

2017
11

80

Number of Patients with a Documented Pre-Diabetes/Diabetes Diagnosis
Number of Patients Without a Documented Pre-Diabetes/Diabetes Diagnosis

Figure 6. Surveyed patients with a documented pre-diabetes or diabetes diagnosis versus
ones without from January 1 through June 30, 2017.
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Number of Patients with Documented Body Mass
Index Greater than 25
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133
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Figure 7. Number of patients seen with a documented body mass index greater than 25.

PAMG Population BMI

78

208

138

Less than 25

Overweight: BMI 25-29.9

Obese: BMI Greater than 30

Figure 8. Body mass index of surveyed population at Park Avenue Medical Group.
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Risk factors associated with a diabetes diagnosis were evaluated in 55 diabetic
patients in the chart review process. Surprisingly, none of the patients with diabetes had
a documented history of cardiovascular disease. Conversely, only 3.6% did not have any
risk factors. A BMI over 25 was the most significant risk factor in common with 96.4%
of the diabetic patient population seen at PAMG, followed by hyperlipidemia (52.7%),
hypertension (41.8%), and high-risk ethnicity (30.9%). Of the 55 diabetic patients
included in the chart review, over 81% of them had two or more risk factors (see Figures
9 through 14).

Risk Factors Associated with Diabetes Diagnosis in
Population Seen at PAMG
20
23

Cardiovascular Disease

45

Hypertension
29

Hyperlipidemia
BMI>25
High Risk Ethnicity

17

2 or More Risk Factors
No Risk factors
53

Figure 9. Risk factors associated with a diabetes diagnosis in the population seen at Park
Avenue Medical Group.
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Risk Factors Associated with Diabetes Diagnosis in
Population Seen at PAMG

No Risk factors

3.60%

2 or More Risk Factors
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Hyperlipidemia

52.70%
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41.80%

Cardiovascular Disease

0%
0%

20%

40%

60%

80%

100%

Figure 10. Differentiation of risk factors associated with a diabetes diagnosis in the
patient population at Park Avenue Medical Group.
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Figure 11. Patient population with documented hyperlipidemia by year.
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Figure 12. Patient population with documented cardiovascular disease by year.

Number of Patients with Documented Hypertension
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Figure 13. Patient population with documented hypertension by year.
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Number of Patients with PCOS or Gestational Diabetes
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Figure 14. Patient population with polycystic ovarian syndrome or gestational diabetes
by year.

To improve sensitivity and specificity in the screening process, the data were
analyzed to identify patients without an existing prediabetes, or diabetes diagnosis with
and without fasting, or random glucose levels at or greater than 100 mg/dL. In total, 28
non-diabetic patients were identified as having blood sugars equal to or greater than 100
mg/dL and have a hemoglobin A1c level falling in the diabetes or prediabetes range (at or
above 5.7). Interestingly, only five individuals were identified in 2015, 10 in 2016, and
13 in the first six months of 2017. These data suggested the providers identified these
patients as “at risk” for diabetes and appropriately screened with a hemoglobin A1c. An
additional 15 patients were identified in 2017 with A1c levels falling in the diabetes or
pre-diabetes range who had a fasting or random glucose level less than 100. These 15
patients were identified when the providers at PAMG began routinely screening with a
hemoglobin A1c as part of their annual wellness blood work and would have been missed

43
using the ADA (2017), WHO (2011b), and USPSTF (2017) screening guidelines. Using
Bowen et al.’s 2017 recommendation to screen all patients with a fasting or random
blood glucose level equal to or greater than 100 mg/dL would have screened an
additional 76 patients who were seen at PAMG for a wellness visit and did not carry a
diabetes diagnosis. Of the 76 identified patients, 39 were not screened with an A1c in
2015, 33 were not screened in 2016, and only four were not screened in 2017 after the
providers modified their screening practices to routinely include a screening A1c in the
adult population, indicating routinely screening with an A1c would capture nearly 10
times more patients with the potential to have an elevated hemoglobin A1c than
screening with a fasting blood glucose alone (see Figure 15).

Non-diabetic Patients with Fasting Glucose level over
100 who Fall in the Prediabetes or Diabetes Range
14
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Figure 15. Non-diabetic patients with fasting plasma glucose levels over 100 mg/dL who
fall within the pre-diabetes or diabetes range.
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Objective One Outcome
Statements
This retrospective study was valuable for statistically describing the population
seen by the providers at PAMG as well as to stratify the risks associated with diabetes in
relationship to non-diabetic, prediabetic, and diabetic populations. While many of the
results paralleled the findings in the research offered by the ADA (2017), some of the
results in the specific patient population at PAMG were not representative of the
literature. For example, the research presented by Bowen et al. (2017) suggested random
blood glucose levels over 100 mg/dL were more predictive of undiagnosed DM than
traditional risk factors; however, the retrospective study identified only 28 individuals or
less than 7% of the selected population with fasting or random blood glucose levels ≥ 100
mg/dL who had an A1c level falling within the diabetes or prediabetes range. Although
more closely related, out of the 106 individuals of a high-risk ethnicity, only 17
individuals or 16% carried a diabetes diagnosis compared to 38 individuals or 11.95% of
the sampled White population with diabetes, indicating a true increased propensity for
individuals from a high-risk ethnicity to develop Type 2 diabetes mellitus.
The data examined in the retrospective study included the entire calendar year of
both 2015 and 2016 and only six months of 2017. The results extracted in each of the
full years were statistically similar and it was anticipated the results for all of 2017 would
also mirror the two previous years. Early in 2017, the providers at PAMG changed their
diabetes screening practices to include routinely screening adult patients with a
hemoglobin A1c. As previously stated, this change in procedure resulted in the
recognition of 15 patients with fasting blood sugars under 100 mg/dL with A1c levels
falling within the diabetes or prediabetes range. In the absence of any other additional
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risk factors recognized by the ADA (2017), WHO (2011b), and USPSTF (2017), this
population of patients would not have been screened utilizing the existing
recommendations, thus delaying interventions aimed at minimizing cardiovascular effects
and end organ damage caused by diabetes. Although respectively small, this group of
patients is representative of the need for changes to the existing recommendations.
The Reach, Efficacy, Implementation
and Maintenance Framework
The reach, efficacy, implementation and maintenance (RE-AIM) framework is a
method used to analyze the strengths and weaknesses of interventions. It can be used to
plan new interventions, change existing interventions or evaluate the impact of
interventions (RE-AIM, 2017). The RE-AIM framework evaluates the reach of an
intervention or the participation rate within the target population; the efficacy, which is
the impact of an intervention on specified criteria; the adoption or percentage of
representativeness of organizations adopting the intervention; the implementation, which
evaluates the quality and integrity of the intervention in a clinical setting; and
maintenance, which evaluates how well the intervention holds up long term (Glasgow,
McKay, Piette, & Reynolds, 2001). The practice of routinely screening adult patients
with a hemoglobin A1c at PAMG was evaluated using the RE-AIM framework to
evaluate the impact of the intervention introduced early in 2017.
Reach. The target population of the screening process initiated in 2017 was all of
the adult patients who presented to PAMG for a wellness exam. The providers, a medical
doctor and a nurse practitioner, began screening all adults in the clinic for a wellness
exam and also began screening patients with symptoms indicative of diabetes. As a
result, 15 patients were newly diagnosed with diabetes or prediabetes and were initiated
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on antihyperglycemic agents or educated on lifestyle or behavioral modifications to
promote risk reduction of diabetes related complications. Additionally, the introduction
of routinely screening adults resulted in a nearly10-fold decrease in the number of
patients with a glucose level falling in the impaired fasting glucose range who were not
previously screened with an A1c.
Efficacy. As previously stated, the impact of initiating the new diabetes
screening practice resulted in the identification of patients with diabetes and prediabetes
who would not have been screened using the ADA (2017), WHO (2011b), and USPSTF
(2017) recommendations unless multiple risk factors were present. Screening all adult
patients with an A1c did indeed effectively screen more patients.
Adoption. Both providers at PAMG adopted the new screening practice, creating
a 100% adoption rate.
Implementation. The degree to which the providers at PAMG consistently
implemented the intervention on the desired population was difficult to determine by
examining the data from the retrospective study alone. Given the results of the study,
screening more patients with an A1c did capture 15 patients with elevated A1c results
falling within the diabetes or prediabetes range in the first six months, suggesting any
degree of implementation improved patient outcomes.
Maintenance. Since the introduction of the diabetes screening practice using the
hemoglobin A1c is in its infancy, more time is required to determine if the intervention is
sustainable over a long period of time. Given the perceived benefit of routinely screening
adults with a hemoglobin A1c, it was anticipated the intervention would be sustained at
PAMG as long as the literature supported the screening practice.
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Evaluation
The use of the hemoglobin A1c as a screening technique on adult patients with
complaints suggestive of a diabetes diagnosis and as a routine intervention at wellness
visits requires a simple and relatively inexpensive blood test. Since many providers use
routine blood testing to screen for a variety of conditions, it is reasonable to adopt the
utilization of the A1c as a screening practice without inconveniencing patients for
additional testing. The obvious benefits include early interventions to modify behavior
and reduce the cardiovascular effects and end organ damage caused by diabetes and
elevated glucose levels.
Other Considerations
The data extracted from the chart review supported the need for more aggressive
Type 2 diabetes screening and risk management. The strongest data derived from the
retrospective chart review supported the use of the hemoglobin A1c as the primary
screening intervention for Type 2 DM. The question of insurance reimbursement and
coverage of the A1c test as a screening method remains at the forefront of discussions
and promotes the underutilization of the A1c for screening purposes. In a publication
released by the Centers for Medicare and Medicaid Services (CMS) in 2016 specifically
addressing Medicare’s coverage of diabetes supplies and services, screening for diabetes
was addressed. Medicare’s diabetes screening coverage previously allowed screening
exclusively with a fasting blood sugar and oral glucose tolerance test. The updated
version allows for up to two screening tests per year for Medicare insured individuals and
covers “fasting blood sugar tests and other tests approved by Medicare as appropriate”
(CMS, 2016, p. 18), dispelling previous language and allowing screening tests beyond a
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fasting glucose level and OGTT. Additional resources were explored to verify equal
insurance coverage through several other large insurance companies. Kaiser Permanente
(2015) also covers fasting blood sugars and hemoglobin A1c tests for screening purposes.
Cigna (2016) follows the guidelines recommended by the USPSTF (2017), which
includes the use of the A1c for screening purposes; similar coverage was documented for
Anthem Blue Cross Blue Shield (Anthem Blue Cross Blue Shield, 2016) and United
Healthcare (UHC; 2015), although with more limitations. United Healthcare’s coverage
of the hemoglobin A1c as a preventative screening test is only covered if the individual
has a history of hypertension with a sustained blood pressure of 135/80.
Objective Two
The second plan objective included a survey of a panel of experts using the
Delphi method to gather information on the utility of a clinical practice guideline. The
expert panel for round one included two physicians, two nurse practitioners, one of which
was a doctor of nursing practice, and a physician’s assistant--all working in family
practices. They were queried about their current screening methods, familiarity of the
ADA (2017), WHO (2011b), and USPSTF (2017) guidelines and about their suggestions
to improve diabetes screening practices.
Participants
The first round Delphi questionnaire was administered to the providers through
SurveyMonkey, an internet survey platform that collects and analyzes data from the
questionnaire and allows the participants’ responses to remain anonymous. The survey
consisting of 18 multiple choice, multiple selection, and short answer questions was sent
to the participants’ email addresses directly from SurveyMonkey. In total, six providers;
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two physicians (MD), three nurse practitioners (APRNs and DNP), and one physician’s
assistant (PA) were invited to participate (see Table 4). The data were not available for
review until the survey closed. Responses were received from 83.3% of the participants
(5/6) and all five responding participants answered all 18 questions. The questionnaire
was open and available for responses for 30 days--opening August 28 and closing
September 28.

Table 4
Delphi Questionnaire Round One Participant Demographics
Participant

Title/Role

Type of Practice

Area Served

#1

MD

Family Medicine

Rural Northern Colorado

#2

APRN, DNP

Family Medicine

Rural Eastern Colorado

#3

PA

Family Medicine

Rural Eastern Colorado

#4

MD

Family Medicine

Rural Northern Colorado

#5

APRN

Family Medicine

Rural Northern Colorado

Results
Results of the first round of the Delphi questionnaire indicated 100% of the
providers considered impaired fasting glucose levels, relatives with diabetes, and history
of gestational diabetes when screening for DM. Eighty percent felt BMI was an
important consideration and 40% of the surveyed participants felt impaired random
glucose levels, age, and ethnicity were also important considerations. One hundred
percent of the participants’ organizations did not use a clinical guideline to screen for
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diabetes and one participant reported personally using the CDC’s (2016) clinical practice
guideline. Sixty percent of the respondents were familiar with each of the ADA (2017),
WHO (2011b), and USPSTF (2017) recommendations for diabetes screening. The
participants were advised to consider the ADA, WHO and USPSTF recommendations,
and to discuss which recommendations they preferred and rationale behind their choice
(see Table 5). The responses were varied and included responses such as “results of the
hemoglobin A1c” and “prefer one or more.” Participants were queried about their
personal preferences for diabetes screening. Eighty percent preferred the hemoglobin
A1c and 20% preferred fasting glucose levels. None of the respondents preferred random
glucose levels or the oral glucose tolerance test. The participants were surveyed with a
question asking if they felt the patient population at their organization was adequately
screened for diabetes. Four of the five responded favorable, stating they were adequately
screened and one participant responded with “no- some at risk patients refuse screening
labs; cost may be a factor.”
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Table 5
American Diabetes Association, World Health Organization and United States
Preventative Services Task Force Recommendations: Provider Preference
Participant

Reasoning

#1

Recommendation Preference
(ADA, WHO or USPSTF)
Prefer more than one

#2

ADA

ADA seems to be most used by
endocrinology & is an easy one to
reference

#3

ADA, WHO

Legitimate

#4

USPSTF

USPSTF-comprehensive review of
studies evaluating benefits/harms of
screening

#5

Results of hemoglobin A1c

A1C, seems to be the most reliable

ADA. More Parameters

The participants were additionally questioned about the utility of a clinical
guideline and if screening/diagnosis would improve if a practice guideline was available
for use. Four of the five participants responded with “yes” and one responded with “no- I
already screen A1c for physicals and patients at risk.” The provider participants were
surveyed about the factors they felt were important to include in a clinical practice
guideline and if there were a perfect guideline, what components would be included. The
participants’ responses included the following:
•

Fasting glucose level

•

A1c

•

Symptoms

•

Past medical history

•

Family history
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•

Age

•

BMI

•

Lab test results

•

Genetic, familial, environmental indications for screening

•

Presence of cardiovascular disease

•

History of gestational diabetes

•

History of elevated lipids

•

All risks

The final question in the survey requested their recommendations on the format of the
clinical guideline. Eighty percent (4/5) preferred a written guideline with an algorithm
and 20% or one participant preferred a written guideline.
Objective Two Outcome
Statements
The results of the round one Delphi survey indicated a clear need and desire for a
single clinical practice guideline to assist providers with diabetes screening. The
screening methods preferred by the providers as well as consideration of risk factors and
preferred guideline components were consistent enough to justify the creation of a
clinical practice guideline. Given the similarity in the participants’ responses, the
creation of a clinical guideline simplistic enough to be used by all family practice
disciplines, containing the elements surveyed as important to the providers, and
remaining consistent with the research and current guidelines should pose no difficulty to
implement.
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Objective Three
Objective three included the creation of the clinical guideline utilizing the current
literature, data collected from the retrospective study, and the expert opinions of the
participants in the first round of Delphi questionnaires. The feedback from the providers
who participated in the Delphi survey played an essential role in the construction of the
clinical guideline. Expert opinion was necessary to ensure the clinical guideline was user
friendly and contained components important to the providers who will utilize the clinical
guideline. The second part of objective three included a second round Delphi
questionnaire designed to query the same group of participants about the usefulness of
the clinical guideline and ensure the components they felt were important were included
in the algorithm and written guideline. Because the majority of queried providers
preferred the elements included in the ADA’s (2017) recommendations, the ADA
recommendations provided the foundation for the development of the clinical guideline.
Elements of Guideline
In addition to ensuring the clinical guideline for this capstone project included the
research from the literature review, data from the retrospective chart review and expert
opinion garnered from the first round of Delphi questionnaire, insurance coverage for
diabetes screening was also considered. As previously addressed, most of the larger
insurance companies and Medicare cover diabetes screening as part of a wellness or
preventative visit. The clinical practice guideline was comprised of a suggested
algorithm, overview, and procedure including recommendations dependent on the results
of a fasting glucose level, A1c, or both.
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Procedure Highlights
To ensure adequate insurance coverage for the patient and provider
reimbursement, the ICD-10 code Z00.00 (encounter for general medical examination
without abnormal findings) or code Z00.01 (encounter for general medical examination
with abnormal findings) should be used (NuMed ICD-10 Lookup, n.d.). Screening labs
including a fasting blood glucose level should be drawn prior to exam or during the
wellness visit. A lipid panel could also be drawn to further stratify the patient’s risk for
developing Type 2 diabetes beginning at age 35 in men and 45 in women (Siu, 2015).
Adults over the age of 40 can have a screening A1c drawn, per the USPSTF
recommendations (Siu, 2015), which are followed by Anthem Blue Cross Blue Shield
(2016), Cigna (2016) and United Healthcare (2015) with an additional hypertension
diagnosis using ICD-10 code Z13.1 (diabetes screening; NuMed ICD-10 Lookup, n.d.).
Adults between the ages of 18 and 44 who have an impaired or abnormal fasting
blood glucose level and have one additional risk factor should also be screened with a
hemoglobin A1c using ICD-10 code R73.09 for abnormal FPG or ICD-10 code R73.01
for impaired FPG (NuMed ICD-10 Lookup, n.d.). An informal risk assessment should be
used in adults ages 18-44 to assist with risk stratification and appropriate use of the
hemoglobin A1c as a screening and diagnostic tool in the diagnosis of Type 2 diabetes
(WHO, 2011a). Individuals in this age group with an impaired fasting glucose level and
one of the following additional risk factor should be routinely screened with an A1c:
•

Impaired Fasting Glucose (100-125 mg/dL)

•

Impaired Random Glucose (126-199 mg/dL)

•

BMI ≥ 25
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•

Age ≥ 45

•

Native American, Black, Hispanic or Asian Ethnicity

•

Hypertension, hyperlipidemia, or cardiovascular disease

•

Relative with diabetes

•

Personal history of polycystic ovarian syndrome (PCOS) or gestational
diabetes

•

Physical inactivity.

Patients with an impaired fasting glucose level should be screened with an A1c if
they are over the age of 45 or at or under the age of 44 and have one additional risk
factor. For individuals with an impaired fasting glucose level and no other additional risk
factors, age appropriate recommendations and annual fasting glucose levels should be
followed. Adults ages 18-44 with an impaired fasting glucose level and normal A1c
should be screened annually with a fasting blood glucose if no other risk factors are
present and they have not previously had an impaired fasting glucose level and an A1c
every three years. Individuals with at least one additional risk factor regardless of age
should have an A1c repeated every three to six months until it becomes abnormal or
repeated glucose levels fall within the normal range. Individuals with an elevated
hemoglobin A1c should be diagnosed with prediabetes or diabetes, managed
appropriately, and retested with an A1c in three to six months. Adults over the age of 45
with normal fasting glucose and A1c levels should have annual fasting blood work
including a lipid panel. Hemoglobin A1c testing should be repeated every three years.
The clinical guideline also contains a statement suggesting patients with
hemoglobinopathies be screened with a two-hour glucose tolerance test instead of the
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A1c. The algorithm offers two clinical pathways depending on age and covers all major
elements addressed in the written clinical guideline on a single page for convenience and
accessibility.
Results of the Round Two Delphi
Questionnaire
Round two of the Delphi questionnaire asked the participants to study and
evaluate the quality of the proposed Diabetes Screening in Adults Clinical Practice
Guideline and Algorithm. The second Delphi questionnaire was administered to the
same panel of expert providers as the first-round questionnaire excluding the one
participant who did not respond to the invitation for the first survey. The participants
were given two weeks to complete the second survey and were queried about the utility
and comprehensiveness of the proposed clinical guideline. The participants were asked
eight “yes” or “no” questions with the goal to obtain at least 70% consensus on the
comprehensiveness and practical use of the proposed guideline and algorithm.
Participants were also encouraged to comment on each of the eight questions and to offer
their opinions about insurance coverage and reimbursement if the clinical practice
guideline was used.
Five of the original participants were invited to complete the second round of
surveys and four of the five finished the questionnaire (80%). The results were
unanimously in favor of the quality and comprehensiveness of the clinical guideline with
one question providing the only exception: “Looking at the written clinical guideline
only, do you feel it is easy to follow?”; 75% of the participants responded “yes” (3/4) and
one participant answered “no” with the following statement: “Algorithms are always
easier to follow.” Included in the second round of questionnaires were questions about
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insurance coverage and reimbursement. All of the provider experts felt the clinical
practice guideline was supportive enough to ensure coverage through the largest
insurance providers. A table was included on both the algorithm and written guideline
listing the aforementioned specific diabetes risk factors to consider for the informal
assessment process. Again, all provider participants felt the table was helpful. Question
7 on the survey asked the participants,
The written guideline offers a statement about the use of the hemoglobin A1c in
patients with sickle cell disease and other hemoglobinopathies (pregnancy,
hemodialysis, recent transfusion or erythropoietin therapy). Were you aware the
2-hour glucose tolerance test is the preferred screening method in this population?
Surprisingly, all of the providers answered “no” to this question, indicating a strong need
for additional education on hemoglobinopathies and use of the A1c.
Objective Three Outcome
Statements
The creation of the Diabetes Screening in Adults Clinical Practice Guideline and
Algorithm proved to be a challenging and worthwhile undertaking. The results of the
second Delphi survey indicated the guideline and algorithm contained the elements
important to the providers, the recommendations of the ADA (2017), and data supported
by the literature review and retrospective study conducted for this project. Participant
provider experts in the Delphi study felt the guideline and algorithm were easy to use and
comprehensive, supporting the objective in the guideline development process.
Objective Four
The plan for implementation was the fourth objective for this DNP capstone
project. Physical implementation was not a defined goal of this objective; however,
objective four included providing the staff at PAMG with the final clinical practice
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guideline for utilization. No formal training was provided as the guideline is
comprehensive and the results of the Delphi survey did not indicate a need for additional
training. The providers were sent the guideline with instructions to contact this
researcher with any questions. If the providers at PAMG decide to implement the
diabetes screening clinical practice guideline, a second retrospective study is
recommended to evaluate pre- and post-implementation results and edit as clinically
necessary or as new evidence dictates.
Facilitators and Barriers to Project Objectives
Key Facilitators
A key advantage to the completion of this capstone project was the ability to use
the EMR system at PAMG. The comprehensive retrospective study portion of this
project would not have been possible without the use of the EMR. The EMR allowed the
researcher to search for individuals who visited the clinic during a specific period of time
for a wellness visit. Additionally, the utilization of the EMR promoted the ability to
examine past medical history and co-morbidities, all which were invaluable in the risk
stratification of the patient population at PAMG. A second key facilitator to this project
was the change made internally to the screening processes in 2017 at PAMG. The
practice of routinely screening adult patients seen for a wellness visit or had multiple risk
factors allowed the researcher to contrast the difference screening with a hemoglobin A1c
made in the same patient population from 2016 when the providers were not routinely
screening with an A1c to 2017. A third key facilitator was the support and participation
from the providers who completed rounds one and two of the Delphi questionnaire. The
responses from the provider participants helped focus the development of the clinical
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practice guideline into an evidence-based, simplistic, and user-friendly tool for diabetes
screening in family practice.
Using the Delphi method to query provider participants through SurveyMonkey
was beneficial in facilitating the completion of project objectives. The responses
remained anonymous; thus, the integrity of the questionnaire results was not questioned.
Providing anonymity for the participants might have played a role in the willingness of
providers to participate. Over 80% of the providers invited to participate completed the
surveys. The SurveyMonkey website application analyzed the results from the Delphi
surveys, taking away some of the data analysis process that was cumbersome. The risk
of data analysis errors was also eliminated with the use of SurveyMonkey’s services.
Key Barriers
Time was the most prominent barrier to the completion of this capstone project.
Objective four included the actual implementation of the guideline, which was not
completed for this project due to time constraints. Following the implementation from
infancy to one-year post-initiation would have allowed the researcher to perform a postimplementation study to observe the effects of the guideline on the practice, providers,
and patient population. Improvements would have been made to the guideline to ensure
it continues to be valuable in evidence-based diabetes screening practices. A second
barrier to the objectives, although also beneficial, was the change to the diabetes
screening practices within PAMG to include screening with a hemoglobin A1c in 2017.
Because a large portion of the proposed clinical practice guideline included screening
with an A1c at various intervals, the effectiveness of the utilization of the guideline on
the providers and patient population could be questioned. Park Avenue Medical Group is
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also a small practice in a rural area with only two providers. The effects of diabetes
screening with the implementation of the guideline created for this project might be
improved if piloted with a larger family practice.
Unintended Consequences
No notable unintended consequences were observed as a result of the completion
of the DNP project objectives; however, the seventh question in round two of the Delphi
questionnaire indicated more provider education is necessary on specific
hemoglobinopathies and the use of the A1c, not only for screening purposes but also for
diabetes management. None of the four participants were aware the hemoglobin A1c
should not be used on certain populations with accuracy; the two-hour OGT test is the
preferred method for diabetes screening and management in this small patient population.
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CHAPTER V

RECOMMENDATIONS AND IMPLICATIONS
FOR PRACTICE

Information garnered from the review of literature described the lack of
congruency in diabetes screening practices nationwide. The recommendations made by
the ADA (2017), WHO (2011b), and USPSTF (2017) are all remarkably similar and
evidence-based, yet rarely used. While there is no clear answer as to why family practice
providers are not following the diabetes screening recommendations made by one or all
three organizations, the results of this project’s Delphi questionnaire indicated a strong
desire to have a single clinical practice guideline to follow within their organizations.
Phase four of this project using the Stetler (2001) model was to physically implement the
clinical guideline. The following recommendations are provided in lieu of the physical
implementation as it was not part of this capstone project.
Recommendations
Results of the literature review, retrospective study, and Delphi surveys supported
the need for a practical tool for diabetes screening in family practice; therefore, it is the
researcher’s recommendation to move forward with the project. The clinical practice
guideline was provided to the providers at PAMG to support their current screening
practices. The timeframe to implement the guideline if desired at PAMG will be left to
the providers’ discretion. The diabetes screening guideline was created to be
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comprehensive enough to include the recommendations of the ADA (2017), WHO
(2011b), and USPSTF (2017), the literature review, and include the preferences of the
providers obtained through the results of the Delphi surveys. Very little training is
required to follow the guideline; however, it is the researcher’s recommendation that new
providers and students be trained on its application to ensure proper use, insurance
coverage, and reimbursement. Periodic review of the ADA, WHO, and USPSTF
recommendations are recommended to ensure the clinical practice guideline is congruent
with the latest evidence-based research. If no changes are made to the guideline, the
researcher recommends an informal retrospective study to ensure this high-risk
population is adequately screened for diabetes and changes are made appropriately.
Consistent adherence to the guideline and algorithm will be necessary to adequately
assess the usefulness of the clinical practice guideline.
As education continues to move toward evidence-based models of study, the
researcher recommends disseminating the clinical practice guideline to other primary care
providers, students, and educational institutions if the information contained in the
practice guideline remains current. Because it is evidence-based and comprehensive
enough to include recommendations from the ADA (2017), WHO (2011b), and USPSTF
(2017), it could be used as a practical tool for understanding current standards of practice.
It is the desire of the researcher for the community of family practice providers to screen
and treat diabetes aggressively to decrease the complications and comorbidities of a
diabetes diagnosis. While the cardiovascular and end organ damaged caused by DM is
irreversible, Type 2 diabetes is one of the few chronic diseases that is reversible. Early
screening and appropriately diagnosing patients with prediabetes allow for initiation of
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lifestyle modifications and behavioral therapy before irreversible physiological damage
ensues. Medicare now covers diabetes self-management training for newly diagnosed
diabetics, diabetics with other risk factors, or poorly managed diabetics. The coverage
allows up to 10 hours of initial training and two additional hours annually if indicated and
teaches patients how to successfully manage their diabetes. Diabetes self-management
training must be prescribed by a provider and can be completed at many federally
qualified health centers (CMS, 2016). Finally, intensive diabetes education is
recommended for patients at risk for developing diabetes as well as newly diagnosed
prediabetics and diabetics. Educating patients is empowering; with empowerment,
providers can help control the information their patients receive, ensure it is accurate, and
limit the amount of bad information received from other sources. This could effectively
place patients in control of their health and lifestyle choices.
Ongoing Evaluations Necessary for Phases Outside the
Scope of the Doctor of Nursing Practice Project
Phase five of the Stetler (2001) model addresses the evaluation of the
intervention. The evaluation process does not need to be completed formally and should
include a cost-benefits analysis (Stetler, 2001). Since this capstone project does not
cover implementation or evaluation, it would be of value for the staff at PAMG to
consider re-evaluating the effectiveness of the diabetes screening guideline after an
informal pilot study. Costs associated with additional blood work, insurance
reimbursement for the facility, and additional out-of-pocket costs absorbed by the
patients should be examined during the evaluation process. Strict adherence to the
guideline is recommended to accurately evaluate the effectiveness of the guideline
intervention.
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Personal Goals and Contributions to
Advanced Practice Nursing
Improving the practice of screening for diabetes in primary care was the principal
goal of this project. It was the researcher’s vision to uncover something uniquely
brilliant in the retrospective study that could facilitate more research in diabetes
diagnostic and screening practices performed in the primary care setting. While that did
not occur, the creation of a comprehensive clinical practice guideline that included
existing research and components of the research completed during this project could be
used to improve screening practices. Proper utilization of the clinical practice guideline
would capture and screen all patients at a high risk for developing Type 2 diabetes. The
specific population for which this guideline would be most beneficial is individuals who
do not have wildly abnormal fasting glucose levels (100-105mg/dL) and a single diabetes
risk factor. This population would be screened with an A1c using criteria outlined in the
guideline created for this DNP capstone project and would have likely been missed using
traditional screening methods, thus delaying treatment. As mentioned previously,
prediabetes carries the same cardiovascular risk as diabetes and microvascular changes
might occur consequentially to unintentional delays in treatment. In an article by Ghody,
Shikha, Karam and Bahtiyar (2015), it was suggested even mildly elevated blood glucose
levels could cause microvascular complications like retinopathy, neuropathy, and
nephropathy (Ghody et al., 2015). Engaging at-risk individuals in treatment options
including lifestyle changes, behavioral modifications, and in some instances
pharmaceutical interventions would minimize cardiovascular changes associated with
diabetes.
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In recent years, there has been a push for higher degrees of education, especially
in health care. The Doctor of Nursing Practice was created to address challenges within
health care and translate knowledge into practice, more specifically evidence-based
practice. The knowledge garnered from DNP programs allows advanced practice nurses
to thrive in leadership roles that improve nursing practice and patient outcomes. The
American Association of Colleges of Nursing (AACN; 2006) released a publication
addressing the essentials of a doctoral education for advanced practice nurses. Within the
AACN’s document is the delineation between research-focused doctoral degrees and
practice-focused. While both doctoral degrees are rigorous and arduous terminal degrees,
the practice-focused degrees rely less on theory and more on practical experiences. The
DNP capstone project is an integrative, immersion experience that challenges DNP
candidates to translate knowledge into practice (AACN, 2006).
The AACN (2006) document includes the following eight competencies that must
be present for attainment of the Doctor of Nursing Practice degree in addition to specialty
competencies advanced practices nurses must complete:
•

Essential I: Scientific Underpinnings of Practice. The scientific
underpinnings of DNP education reflect doctoral level complexities
foundational in nursing including a holistic approach to life processes,
patterns of human interaction with normal life events and the environment,
and nursing processes that create positive changes (AACN, 2006). Within
this essential, doctoral-prepared nurses learn to develop and evaluate new
approaches to practice. Creation of a clinical guideline demonstrated this
competency.
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•

Essential II: Organizational and Systems Leadership for Quality
Improvement and Systems Thinking. According to the AACN (2006), a
DNP graduate who possesses this essential is not only focused on improving
health outcomes but also understands principles of practice management,
assesses policies and procedures, and addresses improvement strategies that
are cost effective and sustainable. Competency was demonstrated within
this essential by the ability of this DNP candidate to assess risks and manage
through collaboration with others using principles of economics, business,
and healthcare policy. The final tenet of this competency is accountability.
The DNP candidate is not only accountable for managing ethical dilemmas
but also ensures the quality of healthcare delivery (AACN, 2006). Although
not always evident, these principles were applied throughout the production
of the project.

•

Essential III: Clinical Scholarship and Analytical Methods for EvidenceBased Practice. This competency is arguably the most important concept of
a DNP education. Bridging the gap between knowledge and practice is the
fundamental tenet of this competency. A DNP graduate must be able to
investigate and synthesize data, isolate facts, and make connections that
hold validity across disciplines (AACN, 2006). Problem solving is achieved
through application of knowledge and shared through dissemination of such
knowledge through projects such as this capstone research project.

•

Essential IV: Information Systems/Technology and Patient Care Technology
for the Improvement and Transformation of Health Care. Information
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systems education and the use of technology to improve healthcare is
instrumental to DNP education. The application of information systems and
technology spans outside the realm of academia and into patient care for
evaluating quality and safety standards, programs of care, and outcomes of
care. This technology is used to perform cost benefits analyses, allow tools
for budgeting, and evaluate consumer health information (AACN, 2006).
Application of this essential was demonstrated through the use of internetbased research and EMR utilization.
•

Essential V: Health Care Policy for Advocacy in Health Care. Healthcare
policy on a broad scale would cover changes in legislation or through other
government actions; while it is necessary for DNPs to be on the forefront of
legislative policy changes, the actions of a DNP educated nurse could also
be witnessed on a smaller scale within organizations. A DNP graduate is
often called upon to facilitate changes in healthcare financing, access,
safety, efficacy, and quality by advocating for policy changes impacting
social justice and equity in health care. Demonstrating leadership and
strength in knowledge of healthcare policy allows the DNP graduate to
influence and implement change at the institutional, local, state, and national
and international levels (AACN, 2006).

•

Essential VI: Interprofessional Collaboration for Improving Patient and
Population Health Outcomes. The Agency for Healthcare Research and
Quality (2016) recently mandated six domains of healthcare quality, which
require a multidisciplinary approach to providing safe, effective, patient-
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centered, timely, efficient, and equitable care. Doctor of Nursing Practice
graduates possess a unique set of skills that allow them to effectively
participate in a collaborative interdisciplinary team and lead when
appropriate. Effective communication and collaborative skills allow the
DNP graduate to lead changes in the delivery of healthcare congruent with
the AACN’s (2006) goals to improve patient outcomes.
•

Essential VII: Clinical Prevention and Population Health for Improving the
Nation’s Health. Population health, health promotion, and disease
prevention are required coursework for the DNP graduate. These classes
place emphasis on promoting health through lifestyle choices and healthcare
decisions, risk reduction and illness prevention, and improving the health of
the community. Many of these skills are taught through evidence-based
recommendations, social determinants of health, and cultural sensitivity.
Doctor of Nursing Practice graduates use their knowledge to evaluate care
delivery models influenced by the community, occupational and
environmental conditions, as well as socioeconomic and cultural dimensions
of health to influence changes geared to improve the health of the
population (AACN, 2006).

•

Essential VIII: Advanced Nursing Practice. The AACN’s (2006)
publication acknowledged the complexity of specialization in advanced
practice nursing. Doctor of Nursing Practice prepared graduates are all
specialists in one or several areas, making their contribution to nursing the
hallmark of the Doctor of Nursing Practice. Experiential opportunities
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gained from each nursing specialty allows the advanced practice nurse to
assess health and illness parameters in complex situations using a holistic
approach, implement therapeutic interventions based on nursing sciences,
create and maintain relationships with patients and other disciplines, and
guide and mentor other nurses to uphold excellence in care delivery
(AACN, 2006). Evidence-based care delivery models are fundamental to
nursing practice and are encouraged throughout all levels of nursing
education.
Summary
As diabetes continues to grow at epidemic proportions, evidence-based diagnostic
and screening interventions are necessary to prevent the concurrent physiological damage
caused by a diabetes diagnosis. Early screening and detection could help minimize the
negative effects of the disease by encouraging early treatment interventions. The
coherence of recommendations made by the ADA (2017), WHO (2011b), and USPSTF
(2017) supported the need for more comprehensive screening in the at-risk population.
Development of a simple, yet comprehensive clinical practice guideline for this DNP
capstone research project was created to facilitate early detection of diabetes or
prediabetes to foster interventions aimed at preventing end organ damage and the
cardiovascular consequences caused by diabetes. Proper guideline utilization would help
identify individual risk factors and stimulate diabetes screening to promote early lifestyle,
behavioral, and pharmacological interventions.
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Phase One: Delphi Study, Round One Questionnaire
The following questionnaire will take approximately 10 – 15 minutes to fill out.
If you think that a colleague would be interested in filling out this questionnaire, please feel free forward
to them the introductory email about this study.
1. What is your current title or role? (You may indicate more than one if applicable)
MD_____ DO _____ APRN _____ PA_____
2. In what kind of practice do you primarily work?
Family Medicine _____
Internal Medicine _____
3. What ages of patients do you primarily see? (You may indicate more than one)
Children (Birth to 12) _____
Adolescents (13-18) _____
Adults (19-39) _____
Adults (40-64) _____ Older Adults (>65) _____
4. What area do you primarily serve?
Denver Metro _____
Rural Northern Colorado _____
Rural Eastern Colorado _____
Other _____ Please Name _______________________________________________________________
_____________________________________________________________________________________
5. Which risk factors do you consider when screening for diabetes?
Impaired fasting blood sugar _____
Impaired random blood sugar _____
Age _____
BMI _____
Gender _____
Ethnicity _____
Blood pressure _____
Relative with diabetes _____
History of gestational diabetes _____
Physical inactivity _____
History of polycystic ovarian syndrome _____
History of cardiovascular disease _____
Other _____ (please list) ________________________________________________________________
6. Do providers at your location utilize any clinical guidelines pertaining to the screening/diagnosis of
diabetes?
Yes ________ No ______
If yes, what do you think are the key components of the clinical guidelines most often used?
______________________________________________________________________________________
______________________________________________________________________________________
______________________________________________________________________________________
__________________________________________________________________________________
7. Do you follow any specific clinical practice guideline pertaining to the screening/diagnosis of diabetes?
No _____
Yes _____ If so, which do you use (please name) ________________________________________
8. Are you familiar with any of the following diabetes screening recommendations?
American Diabetes Association (Updated 1/2017)? _____
World Health Organization (Updated 2016)? _____
United States Preventative Services Task Force (Updated 12/2015)? _____
Note the information attached for each. Would you prefer to follow 1 or more of these, if so which one(s):
______________________________________________________________________________________
______________________________________________________________________________________
___________________________________________________________________________________
If you prefer to follow one, tell me which one and why?
______________________________________________________________________________________
______________________________________________________________________________________
______________________________________________________________________________________
______________________________________________________________________________________
_________________________________________________________________________________
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If you prefer to follow parts of one or more of the above standard guidelines please elaborate (if possible
please be specific) :
______________________________________________________________________________________
______________________________________________________________________________________
______________________________________________________________________________________
______________________________________________________________________________________
_________________________________________________________________________________
9. If there were a perfect guideline what components would it contain?
______________________________________________________________________________________
______________________________________________________________________________________
______________________________________________________________________________________
______________________________________________________________________________________
_________________________________________________________________________________
10. Which method do you prefer for screening for diabetes?
Fasting blood sugar _____
Random blood sugar _____
Hemoglobin A1c _____
Oral glucose tolerance test _____
Other _____ (please name) ______________________________________________________________
11. What factors do you believe should be considered in a diabetes screening guideline?
______________________________________________________________________________________
______________________________________________________________________________________
______________________________________________________________________________________
______________________________________________________________________________________
_________________________________________________________________________________
12. Do you feel the patient population at your organization is adequately screened for diabetes?
Yes _____
No _____
If you checked no above why are your patients not adequately screened? Please be specific.
______________________________________________________________________________________
______________________________________________________________________________________
______________________________________________________________________________________
______________________________________________________________________________________
_________________________________________________________________________________
13. If a comprehensive diabetes screening clinical guideline were available to you or other providers in
your organization, do you think it would improve or increase screening/diagnosis practices?
Yes _____
No _____
If you checked no above why do you think it would not improve or increase screening/diagnosis practices?
______________________________________________________________________________________
______________________________________________________________________________________
______________________________________________________________________________________
______________________________________________________________________________________
_________________________________________________________________________________
14. What guideline format do you prefer?
Written guideline _____
Algorithm only _____
Guideline with an algorithm _____
Other _____ please explain _____________________________________________________________
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15. Are there any comments about the above questions you would like to make?
______________________________________________________________________________________
______________________________________________________________________________________
______________________________________________________________________________________
______________________________________________________________________________________
_________________________________________________________________________________
Thank you for your participation.
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American Diabetes Association Recommendations 2017
Test

Value

Description

Fasting Plasma Glucose

≥ 126 mg/dL

Fasting is defined as no caloric
intake for > 8 hours

2-hour Plasma Glucose

≥ 200 mg/dL

Using WHO guidelines and
glucose load of at least 75 g of
anhydrous glucose

A1c

≥ 6.5%

Lab tested using method that is
NGSP certified and standardized

Random Plasma Glucose

≥ 200 mg/dL

With classic symptoms of
hyperglycemia

The diagnosis of diabetes is made only after repeat confirmation, unless there is a clear clinical diagnosis of
random plasma glucose level ≥ 200 mg/dL in a symptomatic individual (polyuria, polyphagia, polydipsia).
The second test should be conducted as soon as possible and questionable results should be repeated in 3-6
months.
Screen overweight or obese individuals (BMI>25) with one or more risk factors (A1c ≥ 5.7%, impaired
glucose tolerance test (IGT), impaired fasting glucose level (IFT), 1 st degree relative with type 1 DM, high
risk ethnicity, women with history of gestational DM, history of cardiovascular disease, hypertension,
history of PCOS or other diseases causing insulin resistance, physical inactivity)
Routine testing for everyone beginning at age 45 and repeated every 3 years for individuals with normal
results.
More frequent testing is recommended based on risk stratification and prediabetes status.
Yearly monitoring for individuals with a prediabetes diagnosis.
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World Health Organization Recommendations 2016
Test

Value

Fasting Plasma Glucose

≥ 7.0 mmol/L (126 mg/dl)

2-hour Plasma Glucose

≥ 11.1 mmol/L (200 mg/dl)

HbA1c

≥ 6.5%

Diagnosis of DM in an asymptomatic individual:
Should not be based on a single abnormal plasma glucose or A1c level.
A second test with values within the diabetic range is a requirement for diagnosis according to the WHO
standards using fasting, random or oral glucose tolerance testing in a stringently controlled testing or lab
environment.
Periodic retesting is recommended for individuals having a singular positive diagnostic test and negative
second test until DM status is clear.
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United States Preventative Services Task Force Recommendations 2015
Test

Value

Hemoglobin A1c Level

≥ 6.5%

Fasting Plasma Glucose Level

≥ 7.0 mmol/L
≥ 126 mg/dl

2-hour Oral Glucose Tolerance Test

≥ 11.1 mmol/L
≥ 200 mg/dl

Screening Recommendations:
Screen only adult patients ages 40-70 who are asymptomatic and overweight or obese.
Screen individuals with additional at least one risk factors such as family history of diabetes, history of
gestational diabetes, polycystic ovarian syndrome, or persons of high risk ethnicities earlier.
Screening Tests:
HbA1c
Fasting plasma glucose level
Oral glucose tolerance test
Screening Interval:
Every 3 years for initial normal levels
Annual Risk assessment to identify risk factors for abnormal glucose metabolism such as obesity, physical
inactivity, smoking, hypertension and hyperlipidemia
Diagnosis:
Repeat testing with the same test on a different day
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CONSENT FORM FOR HUMAN PARTICIPANTS IN RESEARCH
UNIVERSITY OF NORTHERN COLORADO
INFORMED CONSENT-NO SIGNATURE DOCUMENT
Project Title: Screening for Diabetes in At-Risk Populations in Primary Care
Student Researcher: Vera L. Pillitteri, BSN, RN, DNP-S
Research Advisor: Kathleen N. Dunemn, PhD, APRN, CNM, School of Nursing
Co-Research Advisor: Vicki Wilson, PhD, MS, RN, School of Nursing
Committee Member: Deborah Green, M.D.
Expert Consensus: A Delphi Study

The purpose of the following Doctor of Nursing Practice Research Translation Project is
to develop an evidence-based clinical practice guideline for improved screening methods
in the diagnosis of diabetes in the adult population with one or several risk factors, or
those individuals considered to have an increased risk for the development of type 2
diabetes. Evaluation of current screening practices in the family practice setting will be
conducted. Participation from advanced practice healthcare providers throughout
Colorado will be requested to develop expert consensus in the creation of a user friendly
and simplistic clinical practice guideline.
The Delphi Method originally developed in the 1950’s is a widely used research tool for
surveying expert opinion and consensus on a specific topic or field of study using a
questionnaire. The Delphi method was created to address what could or should be done
in practice and has been fundamental in the development of clinical guidelines. For the
purposes of this project, two rounds of questioning will be administered to the panel of
experts (participants), first addressing observed or utilized diabetes screening practices
using the Delphi Method. The second round of questions will address the proposed
screening guideline, ease of use and prospective utilization. It is anticipated that each
participant will complete each round of the Delphi survey in under 20 minutes. Two
rounds of questioning will be required for this capstone project.
The responses gathered from the surveyed material will be recorded anonymously and
only the student researcher and the research advisor will have access to the original
responses. All Delphi questionnaires will be sent and returned electronically through
private email on a secure server. Participation is voluntary and all responses will be
kept anonymous. The responses will be kept on a password protected USB flash drive
and in the possession of the DNP student. Access will only be granted to the student
researcher and research advisor. Since participation is voluntary and this is a quality
improvement project, there are no foreseeable risks to the participants.
Participation is voluntary. You may decide not to participate in this study and if you
begin participation you may still decide to stop and withdraw at any time. Your decision
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will be respected and will not result in loss of benefits to which you are otherwise
entitled. If you have questions, please contact a member of the research team.
Having read the above and having had an opportunity to ask any questions, please
complete the questionnaire “Phase One: Delphi Study, Round One Questionnaire” if you
would like to participate in this research. By completing the questionnaire and returning
it to the student researcher, it will be assumed that you have communicated consent in
participation. Please print a copy of this form to retain for future reference. Please return
the completed survey to verapillitteri@gmail.com
If you have any concerns about your selection or treatment as a research participant,
please contact Sherry May, IRB Administrator, Office of Sponsored Programs, 25
Kepner Hall, University of Northern Colorado Greeley, CO 80639; 970-351-1910.
Student Researcher: Vera L. Pillitteri, BSN, RN, DNP-S
E-mail: verapillitteri@gmail.com
Phone: 303-517-2981
Research Advisor: Kathleen N. Dunemn, PhD, APRN, CNM
E-mail: Kathleen.Dunemn@unco.edu
Phone: 970-351-3081/303-649-5581
Co-Research Advisor: Vicki Wilson, PhD, MS, RN
E-mail: Vicki.Wilson@unco.edu
Phone: 970-351-1295
Committee Member: Deborah Green, M.D.
Address: Park Avenue Medical Group
315 Park Avenue
Ft. Lupton, CO 80621
E-mail: dgreen.pamg@hotmail.com
Phone: 303-857-6111
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Phase Three: Delphi Study Round Two Questionnaire
Thank you for your participation in the Delphi Study Round Two Questionnaire. The
purpose of this questionnaire is to obtain consensus regarding the proposed clinical
guideline developed for utilization by the providers at Park Avenue Medical Group. The
objective of this guideline is to obtain at least 70% participant consensus on the ease of
use and clinical utility of the proposed guideline and algorithm.
The information gathered from the Delphi Study Round One and the results from a
retrospective chart review utilizing the electronic medical record (EMR) at Park Avenue
Medical Group were used in conjunction with the current evidence-based
recommendations to develop the proposed guideline. The chart review process evaluated
current screening practices, risk factors identified by the American Diabetes Association,
World Health Organization and United States Preventative Services Task Force and the
demographic information on the patient population at Park Avenue Medical Group.
Additionally, random and fasting blood glucose levels at or above 100 mg/dL were
considered and utilized to improve sensitivity and specificity of the diabetes screening
process. Please use the attached information to answer the following questions.
1. 100% of the participants responded that impaired fasting blood glucose levels, a
relative with diabetes or a past history of gestational diabetes are the most
important factors to consider when screening for diabetes, and BMI (80%),
impaired random glucose levels, age and ethnicity (40%) were also important
considerations. Do you feel the attached algorithm adequately considers these
factors?
Yes _____ No _____
If you answered no, what do you feel is missing?
__________________________________________________________________
2. 80% of the Phase One participants do not follow any clinical guideline for
diabetes screening, however prefer the parameters addressed by the American
Diabetes Association’s recommendations (fasting glucose levels, A1c, symptoms,
family history, co-morbidities and BMI). Do you feel the attached algorithm
correctly reflects the ADA’s recommendations? (See the attached ADA
recommendations if you are unfamiliar with them).
Yes _____ No _____
If you answered no, what ADA recommendations do you feel were not
addressed?
__________________________________________________________________
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3. The algorithm utilizes the A1c as a screening method in various stages depending
on age and risk factors. Do you feel using the algorithm would allow adequate
insurance coverage and reimbursement for diabetes screening?
Yes _____ No _____
If you answered no, what additional factors should be considered?
__________________________________________________________________
4. Looking at the written clinical guideline only, do you feel it is easy to follow?
Yes _____ No _____
If you answered no, what areas require clarification?
__________________________________________________________________
5. Again, looking at only the written guideline, do you feel Table 1 is helpful?
Yes _____

No _____

6. Do you feel the inclusion of the ICD 10 codes and CPT codes will be helpful for
ensuring insurance coverage and reimbursement?
Yes _____ No _____
If you answered no, please explain
__________________________________________________________________
7. The written guideline offers a statement about the use of the hemoglobin A1c in
patients with sickle cell disease and other hemoglobinopathies (pregnancy,
hemodialysis, recent transfusion or erythropoietin therapy). Were you aware
the 2-hour glucose tolerance test is the preferred screening method in this
population?
Yes _____

No _____

8. Do you have any additional recommendations about the ease of use or
comprehensiveness of the clinical practice guideline and algorithm?
Yes_____ No _____
If so, what recommendations do you have?
_________________________________________________________________
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CLINICAL PRACTICE GUIDELINE
TITLE: Screening for Type 2 Diabetes Mellitus in the Adult Population Clinical
Practice Guideline
Author: Vera L. Pillitteri BSN, RN, DNP-S
Reviewed: October 2017
Target Population: All adult patients over the age of 45 and adult patients ages 18-44
with one or more risk factor
Rationale: The following practice guideline will assist with differentiating at-risk
populations and model screening practices for type 2 diabetes mellitus in the primary care
setting.
Overview
Screening for type 2 diabetes has been the focus of ongoing efforts to minimize the
cardiovascular consequences and long-term effects of diabetes, however there has not
been consensus on screening practices. A recent survey indicated that while providers
are familiar with the American Diabetes Association, World Health Organization and the
United States Preventative Services Task Force recommendations, they are not being
used to screen for diabetes in the primary care setting.
A retrospective study was conducted to evaluate the screening practices and risk
stratification at a rural family practice. The data was examined to quantify the number of
diabetes related risk factors in the patient population as well as to analyze screening
methods used for a wellness visit in diabetic and non-diabetic patients. The results
indicated routinely screening with only a fasting blood glucose level would fail to capture
a significant number of individuals with a normal fasting glucose level and potentially
elevated hemoglobin A1c results falling within the prediabetes or diabetes range.
Additionally, individuals with impaired fasting glucose levels were either sent for
additional testing, did not follow up or were lost to follow up causing a delay in
treatment. Based on the data collected in the retrospective chart review, performing both,
a fasting blood sugar and hemoglobin A1c on all patients during their annual wellness
visit on adults ages 45 and older, and on adults ages 18-44 with impaired fasting glucose
levels and one additional risk factor would capture nearly 10 times more patients with the
potential to have elevated A1c levels.
The purpose of this practice guideline is to provide a simplistic, yet comprehensive tool
to assist with screening for type 2 diabetes in the primary care setting using the latest
research based evidence from the retrospective study as well as the American Diabetes
Association, World Health Organization and United States Preventative Services Task
Force.
Procedure
For all patients presenting to the clinic for a wellness exam (ICD 10 code Z00.00 or
Z00.01), screening labs including a fasting blood glucose level should be drawn prior to
exam or during the wellness visit. A lipid panel can also be drawn to further stratify the
individual’s risk for the development of type 2 diabetes. Individuals ages 40 and older
should additionally have a screening hemoglobin A1c drawn with fasting labs using the
diabetes screening ICD 10 code Z13.1 and CPT code 82947 for insurance reimbursement.
Adults ages 18-44 who have an impaired fasting blood glucose level (100-125 mg/dL) or
abnormal fasting blood glucose level which includes glucose levels less than 60 mg/dL
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and have at least one of the following additional risk factors should also be screened with
a hemoglobin A1c using ICD 10 code R73.09 for abnormal fasting glucose level or
R73.01 for impaired fasting glucose.
Diabetes Related Risk Factors for Informal Risk Assessment
• Impaired Fasting Glucose (100-125 mg/dL)
•

Impaired Random Glucose (126-199 mg/dL)

•

BMI ≥ 25

•

Age ≥ 45

•

Native American, Black, Hispanic or Asian Ethnicity

•

Hypertension, hyperlipidemia or cardiovascular disease

•

Relative with diabetes

•

Personal history of polycystic ovarian syndrome (PCOS) or gestational
diabetes

•

Physical Inactivity

An informal risk assessment using the above mentioned risk factors should be used in
adults ages18-44 to assist with risk stratification and appropriate use of the hemoglobin
A1c as a screening and diagnostic tool in the diagnosis of type 2 diabetes. Individuals
with an impaired fasting glucose level and one additional risk factor should be routinely
screened with an A1c.
Impaired Fasting Glucose Level: Adult individuals with an impaired fasting glucose
level should be screened with an A1c if they are over the age of 45, or at or under the age
44 and have one additional risk factor. For individuals at or under the age of 44 who
have an impaired fasting glucose level and no other additional risk factors, age
appropriate recommendations and annual fasting glucose levels should be followed.
Impaired Fasting Glucose Level and Normal Hemoglobin A1c: Adult individuals ages
18-44 with an impaired fasting glucose level and normal A1c should be screened
annually with a fasting blood glucose if no other risk factors are present and they have
not had an impaired fasting glucose level in the past, and every three years with a
hemoglobin A1c. For individuals with at least one additional risk factor, regardless of
age, an A1c should be repeated every 3-6 months until it becomes abnormal (5.7 or
higher) or repeated glucose levels fall within the normal range (60-99 mg/dL).
Abnormal (elevated) Hemoglobin A1c: Adult individuals with an A1c level within the
abnormal range (5.7 or higher) should be diagnosed with prediabetes or diabetes,
managed appropriately and retested with an A1c in 3-6 months.
Normal Fasting Blood Glucose and Hemoglobin A1c Level in the 45 and Older
Population: Adults age 40 and older with normal fasting blood glucose levels and
hemoglobin A1c should have annual fasting blood work including a lipid panel, and a
hemoglobin A1c should be repeated every three years.
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Individuals with Sickle Cell Trait or Other Hemoglobinopathies: Adults with sickle
cell disease or other disorders of the red blood cells should be screened with the 2-hour
glucose tolerance test instead of the hemoglobin A1c.
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